



**Europäisches  
Patentamt**

**European  
Patent Office**

**Office européen  
des brevets**

**1 0. 02. 05**

**Bescheinigung**

**Certificate**

**Attestation**

Die angehefteten Unterla-  
gen stimmen mit der  
ursprünglich eingereichten  
Fassung der auf dem näch-  
sten Blatt bezeichneten  
europäischen Patentanmel-  
dung überein.

The attached documents  
are exact copies of the  
European patent application  
described on the following  
page, as originally filed.

Les documents fixés à  
cette attestation sont  
conformes à la version  
initialement déposée de  
la demande de brevet  
européen spécifiée à la  
page suivante.

**Patentanmeldung Nr. Patent application No. Demande de brevet n°**

**03078932.5**

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

**R C van Dijk**





Anmeldung Nr:  
Application no.: 03078932.5  
Demande no:

Anmeldetag:  
Date of filing: 18.12.03  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Universiteit Utrecht Holding B.V.  
Jenalaan 18a  
3584 CK Utrecht  
PAYS-BAS

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se referer à la description.)

Newly identified cholinephosphotransferases and ethanolaminephosphotransferases

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s)  
revendiquée(s)  
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

C12N9/00

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of  
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL  
PT RO SE SI SK TR LI



LA 03.1240 EPP

## Newly identified cholinephosphotransferases and ethanolaminephosphotransferases

5           The present invention relates to polypeptides which transfer phosphocholine and phosphoethanolamine and the newly identification thereof, nucleotide sequences coding for any of these polypeptides and nucleotide sequences complementary thereto, plasmids, vectors and a (micro)organism or cell comprising said nucleotide sequences. Furthermore, the present invention relates to processes to produce

10   cholinephosphotransferases and ethanolaminephosphotransferases like sphingomyelin synthase, ethanolamine phosphorylceramide synthase, phosphatidylcholine:glycoprotein cholinephosphotransferase and phosphatidylcholine:glycolipid cholinephosphotransferase. The present invention also provides the application of said nucleotide sequences to influence the equilibrium reactions or to develop compounds

15   influencing the equilibrium reactions wherein said transferases are involved and the application of said compounds in medical use. Finally, a process has been provided to isolate candidates for functional genes of a previously unidentified enzyme from a huge database.

          Cholinephospho (Ch-P) transferases and ethanolaminephosphotransferases

20   catalyze phosphosphingolipid synthesis in animals and parasites. Sphingomyelin (SM) is an abundant constituent of cellular membranes in a wide range of organisms, from mammals (Ullman and Radin, 1974) and nematodes (Satouchi et al., 1993) to protozoa like the human malaria parasite, *Plasmodium falciparum* (Elmendorf and Haldar 1994). SM is preferentially concentrated in the outer leaflet of the plasma membrane. Its high

25   packing density and affinity for sterols help provide a rigid barrier to the extracellular environment and play a role in the formation of lipid rafts, specialised areas in cellular membranes with important functions in signal transduction and membrane trafficking (Simons and Toomre, 2000; Holthuis et al., 2001). Since the discovery of the 'SM cycle' as a putative signalling system analogous to well-known second messenger

30   systems like the phosphoinositide pathway, SM has emerged to the focus of interest in many research laboratories (Kolesnick and Hannun, 1999; Andrieu-Abadie and Levade, 2002).

-2-

Since the enzyme SM synthase is also able to catalyse the reverse reaction, namely the formation of PC from SM and DAG (Marggraf and Kanfer, 1984, van Helvoort et al., 1994) it may regulate, in opposite directions, the cellular levels of the bioactive lipids ceramide and DAG. The latter two are important regulators of  
5 membrane trafficking, cell proliferation and apoptosis (Kolesnic and Hannun, 1999; Bankaitis, 2002; Brose and Rosenmund, 2002, Pettus et al., 2002). Hence, one may anticipate that the physiological significance of SM synthase goes beyond the formation of SM.

The subcellular localisation of the enzyme has been the subject of numerous  
10 studies. After the initial debate had focused on whether SM synthase is located in the Golgi or at the plasma membrane (Marggraf et al.; Voelker and Kennedy, 1982; Lipsky and Pagano, 1985), subsequent work revealed evidence for the presence of SM synthase activity in both membranes (Futerman et al., 1990; Jeckel et al., 1990; van Helvoort et al., 1994). Whether SM synthesis detected at these locations is due to the presence of  
15 more than one isoform of the enzyme has remained an open issue.

Progress in understanding the biological roles of SM synthesis and its regulation is hampered by the fact that no successful purification of the responsible enzyme has been achieved. Recent work has identified a bacterial SM synthase released from  
20 *Pseudomonas aeruginosa* (Luberto et al., 2003). However, this activity is a soluble protein, hence in contrast to the animal enzyme that is tightly associated with the membrane (Ullman and Radin, 1974; Voelker and Kennedy, 1982). Other efforts focused on the isolation of SM synthase mutants by screening Chinese hamster ovary cells for resistance to a SM-directed cytotoxin (Hanada et al., 1998). Instead of mutants with a primary defect in SM synthase, this method yielded mutants defective in serine  
25 palmitoyltransferase activity or blocked in ceramide transport to the site of SM synthesis (Fukasawa et al., 1999).

In the light of the prior art it is therefore highly desirable to identify and purify SM synthases, the composing amino acid sequence and microorganisms producing the same based on a process comprising the expression of nucleotide sequences coding for  
30 the amino acid sequences.

-3-

## Definitions

Throughout this application the following definitions will be used:

- homology: sharing an ancestral molecule
- 5 - identity: extent to which amino acid sequences are invariant, in other words unchanged
- "conservative" or "non-conservative" mutation: replacement of one amino acid by another which does not change the enzyme function upon alignment (lining up sequences to achieve maximum levels of identity and conservation)
- similarity: percentage of identical amino acids or amino acids with similar properties
- 10 between two sequences.

## Abbreviations

Throughout this application the following abbreviations will be used:

15

*Human (Hu)*

*Caenorhabditis elegans* or *C. elegans (Ce)*

*Drosophila melanogaster (Dm)*

*Saccharomyces cerevisiae (Sc),*

20 *Schizosaccharomyces pombe (Sp)*

*Candida albicans (Ca)*

sphingomyelin (SM)

N-Acyl-D-sphingosine-1-phosphocholine

sphingomyelinase (SMase)

phosphatidyl choline (PC)

1,2-Diacyl-sn-glycero-3-phosphocholine

25 diacyl glycerol (DAG)

sn-1,2-Diacyl glycerol

ceramide (CER)

N-Acyl-D-sphingosine

inositol phosphorylceramide (IPC)

lipid phosphate phosphatase (LPP)

N-(7-(4-nitrobenzo-2-oxa-1,3-diazole)aminocaproyl)sphingosine (NBD-CER)

30 *N*-ethylmaleimide (NEM)

electrospray ionization tandem mass spectrometry (ESI-MS/MS)

-4-

- phytoceramide-based SMs (phytoSM)  
 phosphorylcholine (Ch-P)  
 cytidine-5' diphosphocholine-choline (CDP-Ch)  
 tubovesicular membranes (TVM)  
 5    phosphatidylethanolamine (PE)  
       phosphatidylinositol (PI)  
       phosphatidylserine (PS)  
       phosphatidic acid (PA)  
       phosphatidylglycerol (PG)  
 10    open reading frame (ORF)
- CSS1, CSS2 and CSS3 (for candidate SM synthase family 1-3),  
     -- with human CSS3 $\alpha$ 1 and CSS3 $\alpha$ 2 renamed as *huSMS1* and *huSMS2* and  
     *C. elegans* CSS3 $\alpha$ 1 and *C. elegans* CSS3 $\alpha$ 2 renamed as *ceSMS1* and *ceSMS2*  
 15    -- with human CSS3 $\beta$  renamed as *huSMSr* (SMS related), with mice CSS3 $\beta$   
     renamed as *moSMS1*, with *C. elegans* CSS3 $\beta$  as *ceSMS1* and *Drosophila*  
     CSS3 $\beta$ , as *doSMS1*  
     -- with *C. elegans* CSS3 $\gamma$  renamed as *ceSMSdr*, (SMS distantly related).  
 20    . . . . . Description of the figures with legends.

**Fig. 1. Selection and phylogenetic analysis of candidate SM synthases. (A)**  
 Animal entries in SwissProt/TrEMBL were searched for the presence of a sequence  
 motif shared by LPPs and Aur1p proteins and then further selected on the basis of three  
 25    additional criteria, as indicated. **(B)** Phylogenetic tree of human candidate SM synthases  
 (CSS) and previously characterised members of the human LPP superfamily. **(C)**  
 Phylogenetic tree of CSS proteins from human (*Hu*), mouse (*Mm*), *Caenorhabditis*  
*elegans* (*Ce*) and *Drosophila melanogaster* (*Dm*), and of Aur1p proteins from  
*Saccharomyces cerevisiae* (*Sc*), *Schizosaccharomyces pombe* (*Sp*) and *Candida albicans*  
 30    (*Ca*). Asterisks denote CSS proteins expressed in *S. cerevisiae* and tested for SM  
 synthase activity. SM synthases (SMS) are marked in red. SwissProt/TrEMBL accession



-5-

numbers of CSS proteins are: (1) Q9TYV2; (2) Q20696; (3) Q9VS60/Q9VS61; (4) Q96LT4; (5) Q9DA37; (6) Q86VZ5; (7) Q8VCQ6; (8) Q8NHU3; (9) Q9D4B1; (10) Q9XTV2; (11) Q20735; (12) Q965Q4; (13) Q9D606; (14) Q9NXE2; (15) Q8VCY8; (16) Q96GM1; (17) Q96MP0; (18) AAP57768; (19) Q9BQF9; (20) AAP57767; (21) Q22250; (22) Q9TXU1; (23) Q9VNT9; (24) Q9VNU1; (25) Q10022; (26) Q9D4F2; (27) Q8IY26; (28) Q91WB2; (29) Q96SS7; (30) Q8T8T9; (31) Q22461. Note that (4) Q96LT4 contains a partial protein sequence and that the complete ORF was deduced from a corresponding EST clone (see the Table).

**Fig. 2.** A subset of CSS3 family members displays SM synthase activity upon expression in yeast. (A) Immunoblots of cells expressing various CSS proteins were stained with antibodies recognising the V5 epitope-tagged carboxy termini of CSS proteins. Control denotes cells transformed with empty vector. (B) TLC separation of reaction products generated when NBD-ceramide (NBD-Cer) was incubated with lysates of control or CSS-expressing cells in the presence (+) or absence (-) of IPC synthase inhibitor, aureobasidin A (Aba). (C) Metabolic labelling of cells expressing human CSS3 $\alpha$ 1/SMS1 or CSS3 $\alpha$ 2/SMS2 with [ $^{14}$ C]-choline and NBD-ceramide. The lipids were extracted, separated by two-dimensional TLC and analysed for fluorescence and radioactivity. Note that SMS1- and SMS2-expressing cells, but not control cells, synthesized NBD-SM, and that this NBD-SM was labelled with [ $^{14}$ C]-choline. (D) Metabolic labelling of cells expressing human CSS3 $\alpha$ 2/SMS2 with [ $^{14}$ C]-choline. The lipids were extracted, deacylated by mild alkaline hydrolysis (+NaOH) or control incubated (-NaOH) and separated by two-dimensional TLC before autoradiography. Note that SMS2-expressing cells synthesized alkaline-resistant species of [ $^{14}$ C]-choline-labelled lipids (phytoSM) that were absent in control cells.

**Fig. 3.** NEM inhibits yeast-associated SMase but not mammalian SM synthase. (A) TLC separation of reaction products generated when NBD-SM (1.8  $\mu$ M) was incubated with lysates of exponentially grown yeast cells (20 OD<sub>600</sub> cells) in the presence (+) or absence (-) of *N*-ethylmaleimide (NEM; 1 mM). Reactions were in 0.35 ml RB1 buffer containing 1  $\mu$ g/ml of IPC synthase inhibitor (aureobasidin A) and incubated for

-6-

30 min at 37°C. (B) TLC separation of reaction products generated when NBD-ceramide (NBD-Cer; 1,8 mM) was incubated with lysates of HeLa cells (1/1:  $2 \times 10^6$  cells; 1/4:  $0.5 \times 10^6$  cells) in the presence (+) or absence (-) of NEM (1 mM). Reactions were in 0.35 ml PNS buffer, and incubated for 30 min at 37°C. Lipid extraction and TLC analysis were as described in Materials and methods.

**Fig. 4.** Detergent extracts of human CSS3 $\alpha$ 2/SMS2-expressing yeast cells support SM formation from bovine brain ceramides. Lines A and B show the reconstituted ion chromatograms of m/z 731.6, corresponding to the m/z ratio of protonated 18:0 SM, during the separation of molecular species of choline-containing phospholipids after solid phase extraction of membrane extracts that had been incubated with bovine brain ceramides and egg PC. The elution time of an authentic standard of 18:0 SM is indicated in the chromatogram by an arrow (42.3 minutes). Line A was derived from detergent extracts of human CSS3 $\alpha$ 2/SMS2-expressing cells and line B from detergent extracts of control cells. Mass spectra recorded at the elution time of 18:0 SM confirmed that formation of 18:0 SM occurred in CSS3 $\alpha$ 2/SMS2-containing extracts (top right panel), but not in control extracts (bottom right panel).

**Fig. 5.** SM synthase activity in detergent extracts of human SMS1- or SMS2-expressing yeast cells is stimulated by externally added PC. Detergent extracts of yeast cells expressing human SMS1 or SMS2 were diluted 2- to 8-fold in extraction buffer, and then incubated with NBD-ceramide (1.8 mM) in the presence (+) or absence (-) of externally added PC (22 mM), as described in Materials and methods. Formation of NBD-SM was monitored by one-dimensional TLC.

**Fig. 6.** Human SMS1 and SMS2 function as PC:ceramide choline phosphotransferases. (A) Detergent extracts of yeast cells expressing human SMS1, SMS2 or transformed with empty vector (control) were incubated with NBD-ceramide (1.8  $\mu$ M) in the presence or absence of different potential head group donors (22  $\mu$ M), as indicated. Formation of NBD-SM or NBD-IPC was monitored by one-dimensional TLC and quantified as described in Materials and methods. Note that addition of PI

-7-

stimulated formation of NBD-IPC in all three extracts (asterisks). PC, phosphatidylcholine; SM, sphingomyelin; Ch, choline; Ch-P, phosphorylcholine; CDP-Ch, cytidine-5' diphosphocholine; PE, phosphatidylethanolamine; PI, phosphatidylinositol; PS, phosphatidylserine; PA, phosphatidic acid; PG, phosphatidylglycerol. (B) Detergent extracts of SMS2-expressing and control cells were incubated with NBD-ceramide and [<sup>3</sup>H]-choline labelled PC. The lipids were extracted, separated by two-dimensional TLC and analysed for fluorescence and radioactivity. Note that only SMS2-expressing cells synthesized NBD-SM, and that this NBD-SM was labelled with [<sup>3</sup>H]-choline.

10

**Fig. 7. Human SMS1 and SMS2 exhibit reverse activity.** Detergent extracts of yeast cells expressing human SMS1, SMS2 or transformed with empty vector (control) were incubated with NBD-diacylglycerol (NBD-DAG; 1.8  $\mu$ M) in the presence or absence of different head group donors (22  $\mu$ M), as indicated. Formation of NBD-PC was monitored by one-dimensional TLC and quantified as described in Materials and methods.

15

**Fig. 8. Conserved sequence motifs in SMS1, SMS2 and SMSr proteins.** (A) Alignment of human SMS1, SMS2 and SMSr amino acid sequences. Identical residues are highlighted in black and conservative amino acid substitutions in grey. Conserved residues within four homology motifs, designated D1 to D4, are highlighted in blue and conservative amino acid substitutions in the D2 and D4 motifs of SMSr proteins in green. Note that motifs D3 and D4 display similarity to the C2 and C3 domains in LPPs, with identical residues highlighted in red. Regions predicted to form transmembrane domains, TM1 to TM6, are marked by a black line. (B) Alignment of the four homology motifs in SMS and SMSr proteins from humans (*Hu*), *C. elegans* (*Ce*), *P. falciparum* (*Pf*) and *D. melanogaster* (*Dm*). PlasmoDB accession no. of *Pf*SMS1 and *Pf*SMS2 are MAL6P1.177 and MAL6P1.178, respectively. Putative active site residues in consensus sequences are underlined. Symbols used are n, small neutral amino acid;  $\Phi$ , aromatic amino acid; b, branched amino acid; x, any amino acid.

25

30

-8-

**Fig. 9.** Sequence listings 1 - 11: conserved sequence motifs of phosphotransferases as indicated in figure 8 B

Sequence listings 12 - 22: polypeptide sequences of cholinephosphotransferases and ethanolaminephosphotransferases

12. *human* sphingomyelin synthase 1
13. *human* sphingomyelin synthase 2
14. *human* sphingomyelin synthase related
- 10 15. *Caenorhabditis elegans* sphingomyelin synthase 1
16. *Caenorhabditis elegans* sphingomyelin synthase 2
17. *Caenorhabditis elegans* sphingomyelin synthase 3
18. *Caenorhabditis elegans* sphingomyelin synthase distantly related
19. *Caenorhabditis elegans* sphingomyelin synthase related
- 15 20. *Plasmodium falciparum* sphingomyelin synthase 1
21. *Plasmodium falciparum* sphingomyelin synthase 2
22. *Drosophila melanogaster* sphingomyelin synthase related.

**Fig. 10.** Human SMS1 and SMS2 are encoded by ubiquitously expressed genes. Northern blot analysis of SMS1 and SMS2 transcripts (arrows) in various human tissues. Random prime-labelled human SMS1 or SMS2 cDNA was hybridised to a human poly(A)<sup>+</sup> RNA blot (Origene, Rockville, MD). As a control for loading, the RNA blot was stripped and rehybridized with a human  $\beta$ -actin cDNA probe. Mobilities of RNA size markers are indicated.

25

**Fig. 11.** Human SMS1 and SMS2 localise to different cellular organelles. (A) HeLa cells co-transfected with V5-tagged SMS1 and myc-tagged sialyltransferase were incubated in the presence or absence of 10  $\mu$ M nocodazole for 60 min at 37°C, fixed, and then co-stained with rabbit anti-V5 and mouse anti-myc antibodies. Counterstaining was with FITC-conjugated goat anti-rabbit and Texas red-conjugated goat anti-mouse antibodies. (B) HeLa cells transfected with V5-tagged SMS2 were biotinylated on ice,

30

-9-

fixed and then co-stained with mouse anti-V5 and rabbit anti-biotin antibodies. Counterstaining was with Texas red-conjugated goat-anti mouse and FITC-conjugated goat anti-rabbit antibodies. Bar, 10  $\mu$ m.

5           **Fig.12.** Human SMS2 is partially associated with the Golgi. HeLa cells co-transfected with V5-tagged SMS2 and *myc*-tagged sialyltransferase were incubated in the presence or absence of 10 mM nocodazole for 60 min at 37°C, fixed, and then co-stained with rabbit anti-V5 and mouse anti-*myc* antibodies. Counterstaining was with FITC-conjugated goat anti-rabbit and Texas red-conjugated goat anti-mouse antibodies.  
10       Bar, 10  $\mu$ m.

**Fig. 13.** Membrane topology of human SMS1 and SMS2 proteins. (A) Schematic view of the predicted membrane topologies of V5-tagged SMS1 and SMS2, and the Golgi-associated type I membrane protein, p24. (B) Immunoblot of intact or lysed HeLa  
15       cells expressing V5-tagged SMS1 or SMS2 and pretreated with 8 mM trypsin for 30 min at 30°C in the presence or absence of 0.4% Triton X100, as indicated. Immunoblots were stained with antibodies against the V5 epitope ( $\alpha$ -V5) or against p24 ( $\alpha$ -p24).

20

-10-

**Table: EST clones and primers used in this study**

	Protein name	Accession number <sup>1</sup>	EST clone ID	Primer pairs N- and C-terminal (5'-3')
5	<i>HuCSS1α1</i>	Q9NXXE2	IRAKp961F1432 <sup>2</sup>	AAGCCATGGCTGTAGGAAACAACAC GGTAACTTCGGTCATGGAC
	<i>HuCSS1α2</i>	Q96GM1	IRALp962F0526 <sup>2</sup>	AAGCCATGGCGGGAGGGAGA GGTGGCCACGGCGGGC
	<i>HuCSS2α</i>	Q96SS7	IRALp962I0417 <sup>2</sup>	AAGCCATGCCAGCTTCCCAGAG CCAGGCAGAGATGAGCATC
	<i>HuCSS3α1</i> ( <i>SMS1</i> )	Q86VZ5	LGN01891 <sup>3</sup>	AAGCCATGATCCTTGTAGGACTCTG TGTGTCATTACACCAGCCGG
10	<i>HuCSS3α2</i> ( <i>SMS2</i> )	Q8NHU3	IRAKp961F1433 <sup>2</sup>	AAGCCATGAATATGTTTGATGCTGACA ATCCTTATAAGCCCGTGTGG
	<i>HuCSS3β</i>	Q96LT4	IMAGp958I131239 Q <sup>2</sup>	AAGCCATGGCAGGTCTTAATCAACTC TCCAATTAGTCTTTTCATTATTGC
	<i>MmCSS1α2</i>	Q8VCY8	IRAKp961L1531 <sup>2</sup>	AAGCCATGGCTGGAGGGAG GGTGGCCACGGCGGGC
	<i>MmCSS2α</i>	Q91WB2	IMAGp998B08108 12 <sup>2</sup>	AAGCCATGCCAGCTTCCCAGA CCAGGCAGAGATGAGCATC
15	<i>MmCSS3α1</i> ( <i>SMS1</i> )	Q8VCQ6	IRAKp961L2141 <sup>2</sup>	AAGCCATGAAGGAAGTGGTTTAC TGTGTCGTTTACCAGCCGG
	<i>CeCSS1γ</i>	Q22250	YK289g7 /YK572h5 <sup>4</sup>	AAGCCATGTCCGTGCCAGCTTCG GTACCGATATCCATCATTTTG
	<i>CeCSS3α1</i> ( <i>SMS1</i> )	Q9XTV2	YK559h9 / YK517e10 <sup>4</sup>	AAGCCATGAAAATGTCITGGAATCATC AA TTTTGGCAGAGACATGGTAG
20	<i>CeCSS3α2</i> ( <i>SMS2</i> )	Q20735	YK428e6 / YK109h8 <sup>4</sup>	AAGCCATGACAAACAGTTCGGAGTTC TTGCAATTTGTAGTTGATACGA
	<i>CeCSS3β</i>	Q20696	YK524b8 <sup>4</sup>	AAGCCATGCTGGATAACAGACCTATAC ATTGTGCTTTTGGTATGATTTTG

1 Swiss-Prot/TrEMBL

2 Obtained from RZPD Deutsches Ressourcenzentrum für Genomforschung, Berlin, Germany

3 Provided by Dr. Sumio Sugano, Institute of Medical Science, University of Tokyo, Japan

4 Provided by Dr. Yuji Kohara, National Institute of Genetics, Mishima, Japan

-11-

To achieve the targets of the invention a complementary approach was pursued for the identification of animal SM synthase that takes advantage of structural information available for enzymes catalysing analogous reactions. In contrast to most animal cells, plants, fungi and yeast do not produce SM. Instead, these organisms add phosphoinositol to phytoceramide to generate inositol phosphorylceramide, or IPC (Dickson, 1998). IPC production in the yeast *Saccharomyces cerevisiae* requires the product of the *AURI* gene (Nagiec et al., 1997).

Sequence analysis of Aur1p proteins from different fungi revealed four conserved motifs (Heidler and Radding, 2000) two of which are similar to the C2 and C3 domains present in members of the lipid phosphate phosphatase (LPP) family (Waggoner et al., 1999).

LPPs play a critical role in cell signalling by controlling the conversion of bioactive lipid phosphate esters such as (lyso)phosphatidic acid and sphingosine-1-phosphate to their dephosphorylated counterparts. The conserved C1, C2 and C3 domains in LPPs likely constitute the active site for cleavage of the bond between the lipid hydroxyl and phosphate groups (Neuwald, 1997). In the case of Aur1p, this reaction would represent the first step in the transfer of inositol phosphate from PI, with the resulting enzyme-phosphate intermediate being subjected to nucleophilic attack by the oxygen of ceramide rather than the oxygen of water used by LPPs. The presence of LPP-like motifs, together with the IPC synthase activity found associated with affinity-purified Aur1p, suggests that Aur1p is directly responsible for IPC synthesis.

Insects and mammals contain an ethanolamine phosphorylceramide (EPC) synthase, another phosphotransferase, that may be structurally related to SM synthase. The insect *Drosophila melanogaster* (*Dm*) does not generate SM, but instead produces phosphoethanolamine phosphorylceramide (EPC (Rietveld et al., (17). Moreover, it has been shown that the endoplasmic reticulum of mammalian cells harbours an EPC synthase (Malgat et al., 1987). Furthermore, the nematode *Caenorhabditis elegans* (*Ce*) generates phosphorylcholine-substituted glycolipids (Lochnit, G., et al., 2000) still another phosphotransferase, that may be structurally related to SM synthase.

Based on the above considerations a bioinformatics and functional cloning

-12-

strategy was developed to identify the enzyme responsible for SM synthesis in animals and to identify other cholinephosphotransferases. The present invention provides a surprisingly successful strategy which comprises a process to isolate candidates for functional genes of a previously unidentified enzyme with known activity from a huge database by combining at least four characteristics based on data from bio-informatics and from biochemistry, viz.

- presence of a sequence motif shared with previously identified enzymes having a related function
- biochemical function of the gene should be unknown until now
- no structural homologues in an organism that does not contain the enzyme
- ability to mediate a reaction catalysed by the unidentified enzyme upon its heterologous expression in a organism or cell lacking said enzyme activity.

Preferably also the presence or non-presence of transmembrane domains depending on the working mechanism of the enzyme in relation to the membrane is considered.

By searching the human, mouse, *C. elegans* and *Drosophila* protein databases using a sequence motif shared by LPPs and Aur1p homologues and further selection on the basis of the three additional criteria mentioned above and, a set of cholinephosphotransferase sequences was collected as depicted in Fig. 8B. Conserved residues within a lot of homology motifs have been found.

Therefore, the present invention further provides an isolated polypeptide comprising one or more of the amino acid motifs selected from the group consisting of a sequence of at least 80%, preferably 90 % identity to any of

(a) P-L-X-D-X(35,75)-R-R-X(8)-[YF]-X(2)-R-X(6)-T

(b) C-X-D-X(3)-S-G-H-T

(c) H-Y-[TS]-X-D-[VI]-X(3)-[FYI]-X(6)-F-X(2)-Y-H.

The wording isolated means that said polypeptide has been identified in a



-13-

database comprising a large amount of polypeptides.

In particular said polypeptide is derived from the group consisting of *Animalia*, *Alveolata* and *Kinetoplastida*. Preferably, said polypeptide is selected from the group comprising any of the SEQ ID No. 1 - 11 or at least 70%, more preferably at least 80%,  
5 still more preferably at least 90% similarity to the conserved amino acid motifs listed therein.

Furthermore the present invention provides a polypeptide comprising an amino acid sequence with at least 70%, preferably at least 80% and still more preferably at least 90% similarity to any of the SEQ ID No. 12 - 22. Each of these sequences  
10 comprise amino acid motifs of the SEQ ID No. 1 - 11 or sequences related thereto so that the similarity grade of at least 70 % to any of the SEQ ID No. 12 - 22 will be reached.


The present invention also provides a polypeptide comprising an amino acid sequence with at least 20 % identity to any of the SEQ ID No. 12 - 22. In particular, a  
15 polypeptide comprising an amino acid sequence with at least 30 % identity to SEQ ID No. 12 and therefore at least also including SEQ ID No. 13.

Furthermore, a polypeptide is provided by the present invention comprising an amino acid sequence with at least 40 % identity to any of the SEQ ID No. 19 - 21. Finally, the invention provides a polypeptide comprising an amino acid sequence with at  
20 least 22 % identity to SEQ ID No. 22.

According to a preferred embodiment of the present invention a polypeptide is provided with one or more of the activities selected from the group consisting of cholinephosphotransferases and ethanolaminephosphotransferases, preferably one or more of the activities selected from the group consisting of sphingomyelin synthase, ethanolamine phosphorylceramide synthase, phosphatidylcholine:glycoprotein  
25 cholinephosphotransferase and phosphatidylcholine:glycolipid cholinephosphotransferase. Furthermore, a nucleotide sequence selected from the group consisting of a nucleotide sequence coding for any of the amino acid sequences of a polypeptide with one or more of said activities and an anti sense nucleotide sequence  
30 that is complementary thereto is provided, together with a plasmid, a vector and an organism or micro organism and a cell line comprising said nucleotide sequences.

-14-


According to a further preferred embodiment of the present invention a process is provided for producing sphingomyelin synthase or sphingomyelin comprising the expression of the nucleotide sequences coding for a polypeptide with sphingomyelin synthase activity in a (micro)organism or cell line comprising the nucleotide sequences coding for such a polypeptide. Furthermore, the use of one of more of the nucleotide sequences coding for a polypeptide with sphingomyelin synthase activity to influence the reaction



10

in *vivo* or *in vitro* has been provided. In this way a powerful means has been created to enhance the conversion of CER and PC into SM and DAG and vice versa. Besides this, the present invention also provides the use of one of more of the nucleotide sequences coding for a polypeptide with sphingomyelin synthase activity to identify or develop compounds influencing the reaction


15



According to still a further preferred embodiment of the present invention a process is provided for producing ethanolamine phosphorylceramide synthase or ethanolamine phosphorylceramide comprising the expression of the nucleotide sequences coding for a polypeptide with ethanolamine phosphorylceramide synthase activity in a (micro)organism or cell line comprising the nucleotide sequences coding for such a polypeptide. Furthermore, the use of one of more of the nucleotide sequences coding for a polypeptide with ethanolamine phosphorylceramide activity to influence the reaction

20

25




30

in *vivo* or *in vitro* has been provided. In this way a powerful means has been created to enhance the conversion of CER and PE into EPC and DAG and vice versa. Besides this,

-15-

the present invention also provides the use of one of more of the nucleotide sequences coding for a polypeptide with ethanolamine phosphorylceramide synthase activity to identify or develop compounds influencing the reaction

5



According to another preferred embodiment of the invention the application of the compounds mentioned above which can be identified or developed by the use of one of more of the nucleotide sequences coding for a polypeptide with sphingomyelin  
10 synthase and/or ethanolamine phosphorylceramide synthase in medical use, especially for the manufacture of medicaments treating a disease selected from the group consisting of cancer, metabolic diseases, for instance the Niemann Pick A disease and diseases caused by parasites, for instance malaria, is provided.

According to a further preferred embodiment of the present invention a process  
15 is provided for producing phosphatidyl:glycoprotein cholinephosphotransferase or phosphatidyl:glycolipid cholinephosphotransferase, phosphorylcholine-substituted glycoprotein or phosphorylcholine-substituted glycolipid comprising the expression of the nucleotide sequences coding for a polypeptide with phosphatidyl:glycoprotein cholinephosphotransferase or phosphatidyl:glycolipid cholinephosphotransferase  
20 activity in a (micro)organism or cell line comprising the nucleotide sequences coding for the corresponding polypeptide. "Corresponding" stands for the nucleotide sequences which code for the enzyme with the corresponding activity, so either for the enzyme with the phosphatidyl:glycoprotein cholinephosphotransferase activity or for the enzyme with the phosphatidyl:glycolipid cholinephosphotransferase activity. Furthermore, the  
25 use of one of more of the nucleotide sequences coding for a polypeptide with phosphatidyl:glycoprotein cholinephosphotransferase or phosphatidyl:glycolipid cholinephosphotransferase activity to influence the reaction

30



*in vivo* or *in vitro* has been provided. In this way a powerful means has been created to

-16-

enhance the conversion of glycolipid/protein and PC into PC-substituted glycolipid/protein and DAG and vice versa.

Besides this, the present invention also provides the use of one of more of the nucleotide sequences coding for a polypeptide with phosphatidyl:glycoprotein  
5 cholinephosphotransferase activity or phosphatidyl:glycolipid  
cholinephosphotransferase activity to identify or develop compounds influencing the reaction

10 glycolipid/protein + PC  $\rightleftharpoons$  PC-substituted glycolipid/protein + DAG.

According to another preferred embodiment of the invention the application of the compounds mentioned above which can be identified or developed by the use of one of more of the nucleotide sequences coding for a polypeptide with phosphatidyl:glycoprotein cholinephosphotransferase or phosphatidyl:glycolipid  
15 cholinephosphotransferase in medical use, especially for the manufacture of a medicament treating a disease caused by parasitic nematodes, is provided.

A detailed description of the various aspects of the present invention will be given herebelow.

A novel family of integral membrane proteins likely responsible for SM  
20 synthesis in animal cells was identified according to the process of the present invention. The two human members of this family, SMS1 and SMS2, were subjected to a detailed biochemical analysis and it is believed that their functional assignment as SM synthases is justified on the following grounds.

First, heterologous expression of SMS1 or SMS2 proves sufficient to support  
25 SM synthesis in the yeast *S. cerevisiae*, an organism lacking endogenous SM synthase activity (figures 2, 4 and 6). Second, in keeping with the enzymatic properties of mammalian SM synthase reported in the literature, SMS1 and SMS2 function as bi-directional lipid cholinephosphotransferases capable of converting PC and ceramide to SM and DAG and vice versa (figures 6 and 7). Third, SMS1 and SMS2 localize to  
30 cellular organelles previously established as the principal sites of SM synthesis, namely the Golgi (SMS1) and the plasma membrane (SMS2), figure 11. Fourth, SMS1 and

-17-

SMS2 share sequence motifs containing putative active site residues with lipid phosphate phosphatases and candidate PI:ceramide inositolphosphotransferases (figure 8). Finally, SMS1 and SMS2 adopt a membrane topology whereby the putative active site residues are facing the exoplasmic leaflet (figure 13), hence the side of the membrane where SM synthesis was found to occur.

A multiplicity of SM synthase genes appears widely spread among organisms generating SM. Human SMS1 and SMS2 are highly conserved in mammals and evidence was found for the existence of up to three functional homologues in the nematode *C. elegans*. Moreover, two orthologous sequences in the human malaria parasite *P. falciparum* were identified according to the process of the present invention, suggesting that this lower eukaryote too contains different SM synthases encoded by separate genes. SM synthesis in *P. falciparum* occurs in the Golgi apparatus as well as in the network of tubovesicular membranes (TVM) emerging from the parasitophorous vacuolar membrane during intraerythrocytic development (Elmendorf and Haldar, 1994). A differential sensitivity to 1-phenyl-2-acylamino-3-morpholino-1-propanol has been taken as evidence that the Golgi- and TVM-associated activities correspond to different enzymes (Kauer et al., 1995). Our current findings provide a novel opportunity to test this prediction and may facilitate the development of new drugs against parasites as for instance malaria.

The uniform tissue distributions of transcripts for SMS1 and SMS2 in humans (figure 10) suggest that most mammalian cell types would contain both SM synthase isoforms. Biochemical analysis of human SMS1 and SMS2 thus far revealed no fundamental differences in enzymatic properties, even though the possibility that substrate preferences are lost when enzymes are assayed in a heterologous, detergent-containing system cannot be excluded. For now, the most striking difference between SMS1 and SMS2 concerns their subcellular localisation. While SMS1 seems to represent the well-known Golgi-associated SM synthase, SMS2 primarily resides at the plasma membrane. Hence, SMS1 would be proximal to SMS2 with respect to receiving newly synthesized ceramide from the ER. A challenging prospect is that, whereas the Golgi enzyme would be responsible for generating the bulk of cellular SM, the second enzyme may serve a principal role in signal transduction at the plasma membrane. The

-18-

activation of a sphingomyelinase (SMase) and subsequent liberation of ceramide at the plasma membrane has been recognised as an important signalling event in the regulation of fundamental cellular processes that include cell cycle arrest, differentiation and apoptosis (Kolesnic and Hannun, 1999; Pettus et al., 2002; Andrieu-Abadie and Levade, 2002). By converting ceramide back to SM, plasma membrane-associated SM synthase may attenuate SMase-induced signalling. This reaction would produce as a side product DAG, which is a signalling molecule in its own right (Brose and Rosenmund, 2002). Hence, the presence of a SM synthase at the plasma membrane complicates a proper understanding of the role of ceramide as a specific signal-transducer.

A current bottleneck for elucidating the role of SM hydrolysis in cellular signalling is the unambiguous identification of the agonist-stimulated SMase. Both neutral and acid SMases have been implicated, but their precise cellular roles in SM hydrolysis and signalling remain to be clarified (Andrieu-Abadie and Levade, 2002). Since the plasma membrane-associated SM synthase is capable of catalysing the reverse reaction of SM synthesis (van Helvoort et al., 1994), it is tempting to speculate that it may execute part of the signalling events currently attributed to ligand-induced SMase. The observation that both plasma membrane- and Golgi-associated SM synthases exhibit reverse activity brings up the question of how the directionality of these enzymes is regulated. One possibility is that the direction of the reaction is primarily determined by the relative concentrations of ceramide and DAG in the membrane. On the other hand, given the biological importance attributed to DAG and ceramide, one may expect the interconversion of these molecules to be subjected to a more elaborate form of control. Indeed, it has been shown that activation of SM synthesis in primary astrocytes is an early event associated with the mitogenic activity of basic fibroblast growth factor (Riboni et al., 2001) and that the onset of TNF $\alpha$ -induced apoptosis in rhabdomyosarcoma cells is preceded by TNF-dependent inhibition of SM synthesis (Bourteele et al., 1998). Mammalian SMS1 contains a predicted SAM (sterile alpha motif) domain at the amino-terminus (residues 7-63 in human SMS1) that might provide a means for the enzyme to interact with regulatory proteins (Schultz et al., 1997). The present identification of a family of animal SM synthases offers unprecedented opportunities to further clarify the biological significance of SM metabolism and its

-19-

regulation.

SM synthases contain four highly conserved sequence motifs (figure 8). Two of these, D3 and D4, are similar to the C2 and C3 phosphatase domains in LPPs and include the putative catalytic histidine and aspartate residues implicated in LPP-mediated hydrolysis of lipid phosphate esters (Neuwald, 1997) This suggests a working mechanism for SM synthases in which the catalytic triad previously described for LPPs would function in a similar fashion. The reaction would proceed via the following steps: (1) binding of a two-chain choline-phospholipid (PC or SM) to a unique binding site, (2) nucleophilic attack on the lipid-phosphate ester bond by the histidine in D4 assisted by the conserved aspartate in this motif, (3) formation of a cholinephospho-histidine intermediate and release of DAG or ceramide, facilitated by the histidine in D3 acting as a base, (4) nucleophilic attack of the C1-hydroxyl of ceramide or DAG on the cholinephospho-histidine intermediate, assisted by the histidine in D3, (5) release of SM or PC from the active site to allow another round of catalysis. This model provides a framework for site-directed mutagenesis and kinetic studies to reveal the working mechanism of SM synthases.

There is a striking parallel between animal SM synthase and IPC synthase in yeast. Like human SMS1, the yeast enzyme is Golgi localised and contains the key D4 motif in the Golgi lumen at the start of the last membrane span (Levine et al., 2000). This suggests that animal SM synthase and yeast IPC synthase may have evolved from a common ancestor. In contrast, the SM synthase recently identified from *Pseudomonas aeruginosa* (Luberto et al, 2003) lacks the key motifs of animal SM synthase and is a soluble, rather than an integral membrane protein. Hence, it appears that SM synthases arose at least twice during evolution.

Database searches using the catalytic site sequences from LPPs yielded, in addition to SM synthases, numerous other proteins containing partially conserved phosphatase motifs. In many cases, the biochemical functions of these proteins are not known.

Given the present findings, the possibility that some of these LPP-like proteins do not serve as phospholipases but instead catalyse novel kinds of synthetic or transphosphatidylation reactions deserves consideration. For example, mammals and

-20-

insects synthesize ethanolamine phosphorylceramide, a sphingolipid analogous to SM (Malgat et al., 1986; Rietveld et al., 1999). Whether production of EPC and SM involves a single transferase that accepts both PC and PE as substrates or requires two separate enzymes has remained an open issue. However, *Drosophila* lacks SM and generates only EPC (Rietveld et al., 1999). Our finding that *Drosophila* contains an SMS-related protein, but no SMS proteins, strongly suggests that the SMS-related proteins described in this study function as dedicated EPC synthases. This possibility is currently under further investigation.

Phosphorylcholine (PC), a small haptenic molecule, is found in a wide variety of prokaryotic organisms, i. e. bacteria, and in eukaryotic parasites such as nematodes, as well as in fungi. Linked to parasite-specific glycoprotein glycans or glycolipids, it is assumed to be responsible for a variety of immunological effects, including invasion mechanisms and long-term persistence of parasites within the host. Numerous reports have indicated various effects of PC-substituted molecules derived from parasitic nematodes on signal transduction pathways in B and T lymphocytes, displaying a highly adapted and profound modulation of the immune system by these parasites.

The Nematoda, comprising parasitic and free-living species (e.g. *C. elegans*), can be regarded as promising prototypic systems for structural analyses, immunological studies and biosynthetic investigations. In this context, *Ascaris suum*, the pig parasitic nematode, is an ideal organism for immunological studies and an excellent source for obtaining large amounts of PC-substituted (macro)molecules. *C. elegans*, as a completely genome-sequenced species and expressing parasite analogous PC-substituted structures, together with the possibility for easy *in vitro* cultivation, represents a conceptual model for biosynthetic studies, whereas filarial parasites represent important model systems for human pathogens, especially in developing countries. Current knowledge on the tissue-specific expression of PC epitopes, structural data of glycoprotein glycans and glycosphingolipids bearing this substituent and biological implications for the immune systems of the respective hosts are reviewed by Lochnit et al., 2000. Since the elucidated structures of these compounds are clearly different from those present in the host, the biosynthesis of nematode-specific, PC-substituted compounds would be a promising target for the development of new anthelmintic



-21-

strategies.

It will be clear to the skilled in the art that by the present invention yielding purified cholinephosphotransferases and ethanolaminephosphotransferases a new field of development for new compounds with valuable properties as for instance drugs has been made available. The present invention will further be elucidated by the following examples without in any way restricting the broad scope thereof.

## Materials and methods

### *Chemicals*

Sphingosyl-(NBD-hexanoyl)-phosphocholine (NBD-SM) and (NBD-hexanoyl)-ceramide (NBD-Cer) were from Molecular Probes (Eugene, OR) and Oleoyl-(NBD-hexanoyl)-phosphocholine (NBD-PC) from Avanti Polar Lipids (Alabaster, AL). [methyl-<sup>14</sup>C]-choline was from ICN Biomedicals (Irvine, CA) and L-3-phosphatidyl [N-methyl-<sup>3</sup>H]-choline, 1,2-dipalmitoyl from Amersham Pharmacia (Piscataway, NJ). NBD-DAG was produced from NBD-PC by treatment with phospholipase C from *B. cereus* as described (Trotter, 2000). Egg L- $\alpha$ -phosphatidylcholine, lyso-phosphatidylcholine, L- $\alpha$ -phosphatidylethanolamine, L- $\alpha$ -phosphatidylglycerol, L- $\alpha$ -phosphatidylserine, soybean L- $\alpha$ -phosphatidylinositol, dioctanoyl L- $\alpha$ -phosphatidic acid, SM (from bovine brain), choline, phosphocholine, cytidine 5'-diphosphocholine, O-tricyclo[5.2.1.0<sup>2,6</sup>]dec-9-yl dithiocarbonate potassium salt (D609), N-ethylmaleimide (NEM) and phospholipase C (*Bacillus cereus*) were from Sigma Aldrich (St. Louis, MO).

### *Selection, cloning and expression of CSS sequences*

Animal entries in the Swiss-Prot/TrEMBL protein sequence database were searched using Prosite (<http://www.expasy.org/tools/scanprosite/>) against sequence motif H-[YFWH]-X<sub>2</sub>-D-[VLI]-X<sub>2</sub>-[GA]-X<sub>3</sub>-[GSTA] and then further selected based on three additional criteria as described under Results. Candidate SM synthases (CSS) were assembled into different groups by multiple sequence alignments and phylogenetic trees generated with ClustalW and PHYLIP. Open reading frames (ORFs) in selected CSS sequences were PCR amplified using Taq polymerase (MBI Fermentas, Hanover, MD)

-22-

according to information provided in Table I. PCR products were cloned into yeast expression vector pYES2.1/V5-His-TOPO<sup>s</sup> (Invitrogen Corporation, Carlsbad, CA) and the resulting plasmids used to transform *S. cerevisiae* strain IAY11 (MAT $\alpha$  ura3-52 his3- $\Delta$ 200 leu2-3,-112 trp- $\Delta$ 901 ade2-101 ade3- $\Delta$ 853, provided by Ian Adams, MRC-LMB, Cambridge, UK). Transformants were grown in complete minimal uracil dropout medium containing 2% (w/v) galactose. Expression of CSS proteins was verified by Western blot analysis with mouse anti-V5 antibodies (Invitrogen). PCR amplified ORFs of human SMS1 and SMS2 were cloned into mammalian expression vector pcDNA3.1/V5-His-TOPO<sup>s</sup> (Invitrogen) and the resulting plasmids (SMS1-V5/pcDNA3.1 and SMS2-V5/pcDNA3.1) used to transfect HeLa cells.

#### *SM synthase assay on cell lysates*

CSS-expressing yeast cells were lysed at 100 OD<sub>600</sub>/ml by bead bashing at 4°C in RB1 buffer (120 mM K-glutamate, 15 mM KCl, 5 mM NaCl, 2 mM MnCl<sub>2</sub>, 2 mM MgCl<sub>2</sub>, 20 mM Hepes-KOH, pH 7.2) containing freshly added protease inhibitors (Holthuis et al., (1998).

Lysates were centrifuged at 700 g for 10 min at 4°C and supernatants (0.25 ml per reaction) preincubated with NEM (1 mM) for 10 min at 37°C. The reaction was initiated by addition of 5 nmol of NBD-Cer in 0.1 ml RB1 buffer and incubation continued for 15 min. Lipids were extracted by addition of 1.7 ml chloroform:methanol (1:2.2), dried under N<sub>2</sub> and subjected to butanol/water partitioning. Lipids recovered from the butanol phase were separated by one-dimensional TLC for 30 min in solvent I: chloroform/methanol/4.2 M NH<sub>4</sub>OH (9:7:3, v/v), followed by 30 min in solvent II: chloroform/methanol/acetic acid (45:30:7, v/v). Fluorescent images were recorded on a STORM 860 Imaging Analysis System (Molecular Dynamics, Sunnyvale, CA) and analysed with ImageQuant software.

#### *Metabolic labelling*

CSS-expressing yeast cells (0.5 OD<sub>600</sub>) were inoculated in 5 ml medium containing 10  $\mu$ Ci [*methyl*-<sup>14</sup>C]-choline and 10 nmol NBD-Cer. Cells were grown for 16 h at 30°C,

-23-

washed in water, and lipids were extracted by bead bashing in H<sub>2</sub>O/methanol/chloroform (5:16:16, v/v). The organic extracts were dried under N<sub>2</sub>, subjected to butanol/water partitioning, and lipids recovered from the butanol phase were deacylated by mild base treatment using 0.2 N NaOH in methanol (60 min, 30°C). After neutralizing with 1 M acetic acid, lipids were extracted with chloroform and separated by two-dimensional TLC using solvent I in the first, and solvent II in the second dimension. Radio-labelled lipids were detected by exposure to BAS-MS imaging screens (Fuji Photo Film Co., Japan) and read out on a BIO-RAD Personal Molecular Imager.

#### *Preparation of detergent extracts*

SMS1/SMS2-expressing yeast cells were lysed at 100 OD<sub>600</sub>/ml by bead bashing at 4°C in lysis buffer (50 mM Tris-HCl, pH 7.0, 1 mM EDTA, 0.3 M sucrose) containing protease inhibitors. Post nuclear supernatants were prepared as above and loaded onto a 60% (w/w) sucrose cushion and then centrifuged at 100.000 g for 60 min at 4°C. Membranes derived from ± 500 OD<sub>600</sub> of cells were resuspended in 1 ml ice-cold extraction buffer (50 mM Tris-HCl, pH 7.0, 10% glycerol, 1% Triton X-100, 1 mM MnCl<sub>2</sub>) containing protease inhibitors, incubated for 60 min at 4°C while rotating and then centrifuged at 100.000 g for 60 min at 4°C. Detergent extracts were diluted to a final protein concentration of 1.5 mg/ml in extraction buffer and 100 µl aliquots were snap frozen in liquid N<sub>2</sub> and stored at -80°C.

#### *SM synthase and reverse transferase assays on detergent extracts*

Detergent extracts were diluted 5- to 8-fold in extraction buffer, and 50 µl mixed with 5 µl of a 1.2 mM head group donor stock (e.g. CDP-choline, PC, PI) or with 15 µCi (350-700 fmol) of [<sup>3</sup>H]-choline-containing PC prepared in extraction buffer. Following a 15 min preincubation at 37°C, reactions were started by addition of 220 µl RB2 buffer (50 mM Tris-HCl, pH 7.0, 5 mM MgCl<sub>2</sub>, 1 mM MnCl<sub>2</sub>, 1 mM NEM)

-24-

containing 5 nmol NBD-ceramide (SM synthase assay) or 5 nmol NBD-DAG (reverse transferase assay) and incubated for 60 min at 37°C. Lipids were extracted, separated by TLC, and analysed as above.

5

### *Mass spectrometry*

Detergent extracts (400 µl) were mixed with bovine brain ceramide (180 µM) and egg PC (500 µM) in a total volume of 500 µl. After 15 min at 37°C, reactions were diluted 4-fold in RB2 buffer and then incubated for another 60 min at 37°C. Lipids were  
10 extracted in chloroform:methanol (1:2.2) and subjected to butanol/water partitioning. Residual Triton X-100 was removed by solid phase extraction on Si-60 columns (500 mg stationary phase) in acetone. Phospholipids were eluted in methanol/chloroform (19:1, v/v), dried under N<sub>2</sub>, dissolved in methanol/chloroform (2:1, v/v) and then separated by HPLC on two 250 x 4.6 mm Lichrosphere RP-18 end-capped columns  
15 (Merck, Darmstadt, Germany) in series (Brouwers et al., 1998). The column effluent was split in a 10:1 ratio, with the smaller fraction going to the mass spectrometer. Mass spectrometry was performed on a Sciex API-365 triple quadrupole mass spectrometer (Applied Biosystems, Nieuwerkerk a/d IJssel, The Netherlands). Positive ions were generated by a turbo-ion spray ionisation source operating at +5.5 kV ionisation  
20 potential. N<sub>2</sub> (2 l/min) was used as drying gas at a temperature of 350°C. The declustering potential (cone voltage) was set to 45V and the focus potential to 220V. Mass spectra from mass to charge ratio (m/z) 650 amu to 950 amu were recorded at a speed of 120 amu/s.

25

### *Mammalian cell transfection and immunofluorescence microscopy*

HeLa cells were cultured in DMEM medium containing 10% fetal calf serum. Cells were grown on glass coverslips to 40% confluence and then transfected with human SMS1-V5/pcDNA3.1, SMS2-V5/pcDNA3.1 and myc-tagged  
30 sialyltransferase/pCB7 constructs using Lipofectamine 2000 (Invitrogen). After 48 h, cells were fixed in 3% paraformaldehyde/PBS and processed for immunofluorescence

-25-

microscopy (see Supplementary materials for details). For cell surface biotinylation, cells were incubated twice with 0.5 mg/ml sulfo-NHS-SS-biotin (Pierce) in PBS for 20 min on ice, quenched in 10 mM glycine/PBS for 20 min and then washed in PBS prior to fixation. Immunostaining was with rabbit anti-V5 antibodies (Sigma), mouse anti-V5 antibodies (Invitrogen), mouse 9E10 anti-myc antibody (SanverTech, CA), rabbit anti-biotin antibodies (Rockland, Gilbertsville, PA), FITC- or Texas Red-conjugated goat anti-rabbit and goat anti-mouse antibodies (Jackson Laboratories, West Grove, PA). Images were obtained using a Nikon D-eclipse C1 confocal microscope.

#### *Protease protection assay*

HeLa cells transfected with human SMS1-V5 or SMS2-V5 constructs were washed, scraped and then lysed in ice-cold PNS buffer (120 mM K-glutamate, 15 mM KCl, 5 mM NaCl, 2 mM MnCl<sub>2</sub>, 0.8 mM CaCl<sub>2</sub>, 2 mM MgCl<sub>2</sub>, 1.6 mM EDTA and 20 mM Hepes-KOH, pH 7.2) by 20 passages through a 26<sup>3</sup>/<sub>4</sub> gauge needle. The homogenate was treated with 8 mM trypsin (Sigma Aldrich) in the presence or absence of 0.4% Triton X-100 for 30 min at 37°C. Alternatively, cells were only washed and then trypsin-treated in PNS buffer as above. Homogenates and cell suspensions were transferred on ice, trypsin inhibitor (Sigma Aldrich) was added to 160 mM and samples were processed for Western blot analysis using mouse anti-V5 antibodies and rabbit anti-p24 protein (Gommel et al., 1999, provided by B. J. Helms, Faculty of Veterinary Medicine, Utrecht).

#### *SDS-PAGE and Western Blot Analysis*

Protein extracts were prepared in SDS/Urea sample buffer (20 mM Tris-HCl, pH 6.8, 1 mM EDTA, 4.5 M urea, 2.5% SDS, 0.01% bromophenol blue) containing fresh protease inhibitors (Holthuis et al., (1998). Extracts were heated for 10 min at 50°C, centrifuged briefly at 14,000 g and then resolved by SDS-PAGE on 10% polyacrylamide mini-gels. For Western blotting, nitrocellulose transfers were blocked for 90 min in PBS, 5% Protifar (Nutricia, Zoetermeer, The Netherlands), 0.2% Tween-20 (Blotto). Primary antibody incubations were performed for 1 h in Blotto. Detection was with

-26-

horseradish peroxidase-conjugated goat anti-rabbit or anti-mouse IgG, using enhanced chemiluminescence (Amersham Pharmacia Biotech).

### *Immunofluorescence Microscopy*

5           HeLa cells were grown on coverslips, transfected with human SMS1-V5/pcDNA3.1, SMS2-V5/pcDNA3.1 and *myc*-tagged sialyltransferase/pCB7 (Sprong et al., 2001). 48 h after transfection, cells were fixed in 3% paraformaldehyde/PBS for 30 min at room temperature, quenched in PBS containing 50 mM NH<sub>4</sub>Cl, and then blocked and permeabilized for 1 h in PBS containing 0.5% BSA, 0.1% saponine (blocking  
10           buffer). Cells were labelled with mixtures of primary antibodies (1:200) for 1 h in blocking buffer, washed for 45 min in blocking buffer with three buffer changes, and then incubated for 20 min with 10% goat serum in blocking buffer. For immunostaining of intact cells, incubation with primary antibodies occurred before fixation and was performed for 1 h at 4°C in PBS containing 0.5% BSA. Cells were counterstained with  
15           fluorescently labelled secondary goat antibodies (1:75) for 30 min in blocking buffer, washed in blocking buffer for 45 min with three buffer changes, and then rinsed briefly in PBS and water. Mounting was in Mowiol 4-88 (Calbiochem, La Jolla, CA) containing 2.5% 1,4-diazabicyclo[2.2.2]octane (Sigma).

-27-

## Example 1

## Identification of candidate SM synthases from the animal database

Figure 1A shows an outline of the bioinformatics approach used to identify candidate sequences for SM synthases from the animal database. Candidate SM synthases were identified based on the following criteria: 1) presence of a sequence motif, H-[YFWH]-X<sub>2</sub>-D-[VLI]-X<sub>2</sub>-[GA]-X<sub>3</sub>-[GSTA], shared by previously characterised LPPs and Aur1p homologues; 2) biochemical function should be unknown; 3) no structural homologues in *S. cerevisiae*, since this organism lacks SM; 4) presence of multiple (>2) transmembrane domains, since the enzyme mechanism is intramembranous and because LPPs and Aur1p proteins have 6 predicted membrane spans. Sequences conforming to all 4 criteria were subsequently used as queries in a BLAST search to track down homologous sequences that were missed in the initial search due to deviations in the LPP/Aur1p motif. This approach yielded 9 human, 9 mouse and 9 *C. elegans* sequences that could be grouped into three major protein families, designated CSS1, CSS2 and CSS3 (for candidate SM synthase family 1-3; Figure 1B, C). Except for the presence of a common sequence motif, CSS proteins displayed no significant sequence similarity to Aur1p proteins or to LPP family members with known biochemical functions. However, human CSS1β1 is identical to PRG1, a neuron-specific candidate phosphatidic acid phosphatase with a role in axon growth and regenerative sprouting (Brauer et al., 2003). Database accession numbers of CSS proteins are listed in the legend of Figure 1.

## Example 2

A subset of CSS3 family members displays SM synthase activity

To investigate whether any of the three CSS families indeed contained SM synthases, the open reading frames of human, mouse and *C. elegans* members for which full-length cDNAs could be obtained were cloned into a yeast multicopy, GAL1 promotor plasmid in frame with a carboxy-terminal V5 epitope. The resulting plasmids were used to transform wild-type yeast and the transformants were shifted to galactose-

-28-

containing medium to induce expression of recombinant proteins. Expression of proteins was verified by Western blot analysis using anti-V5 antibodies (Figure 2A). Thus, 13 of the 27 selected CSS sequences were expressed and analysed for SM synthase activity (marked by asterisks, Figure 1C). To this end, yeast cells expressing CSS protein were lysed and incubated with fluorescent  $C_6$ -NBD-ceramide (NBD-Cer), a known substrate of mammalian SM synthase. Incubations were performed in the presence of N-ethylmaleimide (NEM), a potent inhibitor of yeast-associated SMases that does not affect mammalian SM synthase (Figure 3). Reaction mixtures were next subjected to one-phase lipid extraction and the lipids separated by one-dimensional TLC.

Figure 2B shows that in lysates of control cells NBD-Cer was converted exclusively into NBD-IPC. The same was true for lysates of cells expressing members of the CSS1 and CSS2 protein families. However, in lysates of cells expressing human CSS3 $\alpha$ 1, human CSS3 $\alpha$ 2, *C. elegans* CSS3 $\alpha$ 1 or *C. elegans* CSS3 $\alpha$ 2, NBD-Cer was converted to a second product with an Rf value identical to that of NBD-SM. The identity of this product as NBD-SM was confirmed by electrospray ionisation tandem mass spectrometry (ESI-MS/MS; data not shown). Moreover, metabolic labelling of cells expressing human CSS3 $\alpha$ 1 or CSS3 $\alpha$ 2 with [ $^{14}$ C]-choline in the presence of NBD-Cer resulted in the production of radio-labelled NBD-SM (Figure 2C). When NBD-Cer was omitted, we noticed that CSS3 $\alpha$ 2-expressing cells generated small amounts of [ $^{14}$ C]-choline-labelled lipids that were absent in control cells and distinct from PC and lysoPC. In addition, these lipids were resistant to mild alkaline hydrolysis, suggesting that they represent phytoceramide-based SMs (phytoSM; Figure 2D). Importantly, ESI-MS revealed that bovine brain ceramides incubated with detergent extracts of CSS3 $\alpha$ 2-expressing cells, but not control cells, are converted to SM (Figure 4). Together, these results indicate that CSS3 $\alpha$  proteins do not only use NBD-Cer, but also recognise naturally occurring ceramides as substrates for SM synthesis.

Human CSS3 $\alpha$ 1 and CSS3 $\alpha$ 2 share 57% sequence identity and are highly conserved in mammals (human – mouse > 90%). Based on the results presented herein, we propose to rename these proteins SMS1 and SMS2, respectively. *C. elegans* CSS3 $\alpha$ 1 (ceSMS1) and CSS3 $\alpha$ 2 (ceSMS2) share 22-27% sequence identity with human SMS1



-29-

and SMS2, and apparently represent their functional counterparts in the nematode (Figure 2B). *C. elegans* contains a third, CSS3 $\alpha$ -related protein, termed ceCSS3 $\alpha$ 3.

Although we have not tested this protein for SM synthase activity, the finding implies that *C. elegans* is equipped with three independent SM synthases (Figure 1C). BLAST searches for orthologous sequences identified two proteins in the human malaria parasite *Plasmodium falciparum* (PlasmoDB accession no. MAL6P1.177 and MAL6P1.178; see also below). Hence, a multiplicity of SM synthase genes appears a general feature of organisms generating SM.

Apart from CSS3 $\alpha$ /SMS proteins, the CSS3 family contains a second cluster of CSS3 $\beta$  or SMS-related (SMSr) proteins with members in *humans*, mice, *C. elegans*, and *Drosophila* (Figure 1C). Human SMSr is highly conserved in mammals (human-mouse: 95%), shares > 40% sequence identity with its orthologues in *C. elegans* and *Drosophila*, and is about 34% identical to human SMS1 and SMS2. Heterologous expression of human or *C. elegans* SMSr did not yield any detectable SM synthase activity (Figure 2B, right panel). The *C. elegans* CSS3 $\gamma$  protein, renamed SMSdr, is only distantly related to SMS and SMSr proteins (<22% identical; see also Figure 1C) and its ability to mediate SM synthesis was not tested.

### Example 3

Human SMS1 and SMS2 function as PC:ceramide cholinephosphotransferases with reverse activity

SM synthesis in animals proceeds by the liberation of phosphorylcholine from PC and its subsequent transfer onto the primary hydroxyl of ceramide. To establish whether human SMS1 and SMS2 function as PC:ceramide cholinephosphotransferases, their enzymatic characteristics were analysed in more detail. Hence, different donors of choline-P were tested as substrates for SM synthesis. To this end, detergent extracts of cells expressing human SMS1 or SMS2 were incubated with NBD-Cer and the formation of NBD-SM was monitored by TLC. A dilution of extracts proved necessary to render SMS-mediated synthesis of NBD-SM dependent on externally added head group donors (Figure 5). Under these conditions, free phosphorylcholine (Ch-P) and

-30-

CDP-choline (CDP-Ch) did not support SMS1- or SMS2-mediated SM synthesis (Figure 6A). PC, on the other hand, was efficiently recognised as substrate. SM itself was also used as a donor of the phosphorylcholine group. Lyso-PC was a very poor substrate. These results suggest that human SMS1 and SMS2 are transferases that  
5 require two fatty chains on the choline-P donor molecule in order to be recognised efficiently as a substrate.

#### Example 4

The reaction of human SMS1 or SMS2 with non-choline phospholipids

10

We next investigated the possibility that human SMS1 or SMS2 would use non-choline phospholipids as substrates. None of the phospholipids tested (PE, PI, PS, PA, PG) other than PC supported SM formation (Figure 6A). Moreover, when extracts of cells expressing SMS2 were incubated with PC containing [<sup>3</sup>H]-choline, the formation  
15 of radiolabelled NBD-SM was observed (Figure 6B). Hence, it appears that SMS1 and SMS2 directly and specifically recognise the choline head group on their substrates.

#### Example 5

The reaction of sphingomyelin and diacyl glycerol

20

Previous work suggested that mammalian SM synthase is also capable of catalysing the reverse reaction, namely the formation of PC from SM and DAG (Marggraf and Kanfer, 1984; van Helvoort et al., 1994).

To investigate whether this was also the case for human SMS1 and SMS2,  
25 extracts of cells expressing these proteins were incubated with NBD-DAG and the formation of NBD-PC monitored by TLC. Addition of SM induced NBD-PC formation in extracts of SMS1- or SMS2-expressing cells, but not in control cell extracts (Figure 7). Strikingly, PC itself proved more efficient than SM in stimulating SMS1- or SMS2-dependent NBD-PC formation. In contrast, addition of non-choline phospholipids (e.g.  
30 PI) had no effect. These data suggest that human SMS1 and SMS2, rather than

-31-

functioning strictly as SM synthases, are transferases capable of using PC and SM as phosphocholine donors to produce PC or SM, dependent on the relative concentrations of DAG and ceramide as phosphocholine acceptors, respectively.

Mammalian SM synthase was found to be sensitive to the bacterial PC-phospholipase C inhibitor, D609 (Luberto and Hannun, 1998).  
In lysates of SMS1- or SMS2-expressing yeast cells, D609 inhibited SM synthesis in a dose-dependent manner. The extent of inhibition observed for SMS1-mediated SM synthesis (50% at 100 mg/ml D609) was comparable to that reported for mammalian SM synthase (Luberto and Hannun, 1998). SMS2 proved two-fold less sensitive to the drug.

Hence, human SMS1, SMS2 and the mammalian SM synthase activity described in the literature share many enzymatic characteristics.

#### Example 6

#### Structure and expression of human SMS1 and SMS2

Figure 8A shows a sequence alignment of human SMS1, SMS2 and SMSr. Hydrophobicity analysis predicted six membrane-spanning alpha helices connected by hydrophilic regions that would form extramembrane loops. A comparative analysis with SMS and SMSr sequences from mice, *C. elegans*, *P. falciparum* and *Drosophila* revealed that the number and spacing properties of transmembrane helices are well conserved. In addition, SMS proteins contain four highly conserved sequence motifs, designated D1, D2, D3 and D4 (Figure 8A and B, residues highlighted in blue). Motifs D3 (C-G-D-X<sub>3</sub>-S-G-H-T) and D4 (H-Y-T-X-D-V-X<sub>3</sub>-Y-X<sub>6</sub>-F-X<sub>2</sub>-Y-H) are similar to the C2 and C3 motifs in LPPs (shared residues highlighted in red) and include the histidine and aspartate residues (underlined) that form a catalytic triad mediating the nucleophilic attack on the lipid phosphate ester bond Neuwald (1997).

As in LPPs, these residues are juxtaposed to transmembrane segments 4 and 6 of the SMS proteins and consequently would be oriented toward the same side of the membrane. This would suggest that motifs D3 and D4 are part of the catalytic site responsible for liberating cholinephosphate from PC during SM synthesis. Motifs D1

-32-

(P-L-P-D) and D2 (R-R-X<sub>6</sub>-Y-X<sub>2</sub>-R-X<sub>6</sub>-T), on the other hand, appear entirely unique to SMS proteins and are located in the first extramembrane loop and third transmembrane helix, respectively (Figure 8A). The SMSr proteins found in humans, mouse, *Drosophila* and *C. elegans* each contain exact copies of the D1 and D3 motifs, yet exhibit one or  
5 more conserved amino acid substitutions in motifs D2 and D4 (Figure 8A and B, residues highlighted in white on grey.

Previous work showed that some members of the mammalian LPP superfamily are expressed in only a limited set of tissues (Waggoner et al., 1999, Brauer et al, 1997). Since differences in tissue distribution would provide a possible explanation for the  
10 existence of two different SM synthase isoforms in mammals, we investigated the expression profiles of human SMS1 and SMS2. As shown in Figure 10, Northern blot analysis detected the presence of a low abundant 3.8 kb transcript for SMS1 in human brain, heart, kidney, liver, muscle and stomach. A major 1.9 kb transcript for SMS2 was expressed to a similar level in all of the above human tissues. These results suggest that  
15 human SMS1 and SMS2 are encoded by ubiquitously expressed genes.

#### Example 7

##### Subcellular localisation and membrane topology

20 SM synthesis occurs in the Golgi complex as well as at the plasma membrane of mammalian cells. Endosomes have been put forward as another major site of SM synthesis (Kallen et al., 1994) but this has been disputed (van Helvoort et al., 1994).

It is not known whether SM synthase activity detected at these locations is due to the presence of more than one iso-enzyme in the cell. This led us to examine the  
25 subcellular distribution of V5-tagged versions of human SMS1 and SMS2 in transfected HeLa cells using immunofluorescence microscopy. As shown in Figure 11A, SMS1 was concentrated in the perinuclear region where it displayed extensive colocalisation with sialyltransferase, a marker of trans Golgi cisternae. This colocalisation was also observed in cells treated with nocodazole, a drug causing fragmentation of the Golgi by  
30 disrupting the microtubular network, hence confirming the association of SMS1 with the Golgi apparatus. SMS2 displayed a different localisation pattern and was primarily

-33-

concentrated at the plasma membrane (Figure 11B). A portion of SMS2 was also found in the perinuclear region where it colocalised with sialyltransferase (see Figure 12). This Golgi-associated pool of SMS2 unlikely represents newly synthesized material en route to the cell surface, since it was also observed in cells after a 4-hour chase with  
5 cycloheximide. There was no substantial colocalisation of SMS2 with markers of the endosomal/lysosomal system (e.g. EEA1, CD63, internalised transferrin; data not shown). Whether SMS2 cycles between the Golgi and the plasma membrane, and thereby passes through endosomes remains to be established.

Since SM synthesis takes place in the exoplasmic leaflet of the Golgi and the  
10 plasma membrane (Futerman et al., 1990; van Helvoort et al., 1994), the putative catalytic residues in motifs D3 and D4 of SMS1 and SMS2 would be oriented toward the Golgi lumen and cell surface, respectively, whereas their termini would be located on the opposite, cytosolic side of the membrane (Figure 13A). To test this prediction, we investigated the sidedness of the V5-tagged COOH termini of human SMS1 and SMS2  
15 by protease protection analysis. When HeLa cells transfected with the SMS2-V5 associated type I membrane protein, p24 construct were trypsinised, the V5 tag remained intact, unless cells were lysed or treated with detergent prior to incubation with the protease (Figure 13B). Trypsinisation of lysates from SMS1-V5 expressing cells in the absence of detergent resulted in a complete removal of the V5 tag. Under  
20 these conditions, the Golgi-associated type I membrane protein, p24 (Gommel et al., 1999).

was largely protected. Collectively, these results indicate that the COOH termini of SMS1 and SMS2 are cytosolic. Consequently, the putative active site residues in these proteins would be positioned on the exoplasmic leaflet (Figure 13A), hence where SM  
25 synthesis was found to occur. Together, these findings demonstrate yet another level of similarity between SMS1, SMS2 and the SM synthase activity previously described in mammalian cells.

-34-

## References

- Andrieu-Abadie, N. and Levade, T. (2002) Sphingomyelin hydrolysis during apoptosis. *Biochim. Biophys. Acta*, 1585, 126-134.
- 5 Bankaitis, V.A. (2002) Cell biology. Slick recruitment to the Golgi. *Science*, 295, 290-291.
- Bourteele, S., Hausser, A., Doppler, H., Horn-Muller, J., Ropke, C., Schwarzmann, G., Pfizenmaier, K. and Muller, G. (1998) Tumor necrosis factor induces ceramide oscillations and negatively controls sphingolipid synthases by caspases in apoptotic
- 10 Kym-1 cells. *J. Biol. Chem.*, 273, 31245-31251.
- Brauer, A.U., Savaskan, N.E., Kuhn, H., Prehn, S., Ninnemann, O. and Nitsch, R. (2003) A new phospholipid phosphatase, PRG-1, is involved in axon growth and regenerative sprouting. *Nat. Neurosci.*, 6, 572-578.
- Brose, N. and Rosenmund, C. (2002) Move over protein kinase C, you've got company.
- 15 *J. Cell Sci.*, 115, 4399-4411.
- Brouwers, J.F., Gadella, B.M., van Golde, L.M. and Tielens, A.G. (1998) Quantitative analysis of phosphatidylcholine molecular species using HPLC and light scattering detection. *J. Lipid Res.*, 39, 344-353.
- Dickson, R.C. (1998) Sphingolipid functions in *Saccharomyces cerevisiae*: comparison
- 20 to mammals. *Annu. Rev. Biochem.*, 67, 27-48.
- Elmendorf, H.G. and Haldar, K. (1994) *Plasmodium falciparum* exports the Golgi marker sphingomyelin synthase into a tubovesicular network in the cytoplasm of mature erythrocytes. *J. Cell Biol.*, 124, 449-462.
- Fukasawa, M., Nishijima, M. and Hanada, K. (1999) Genetic evidence for ATP-
- 25 dependent ER-to-Golgi apparatus trafficking of ceramide for sphingomyelin synthesis in CHO cells. *J. Cell Biol.*, 144, 673-685.
- Futerman, A.H., Stieger, B., Hubbard, A.L. and Pagano, R.E. (1990) Sphingomyelin synthesis in rat liver occurs predominantly at the cis and medial cisternae of the Golgi apparatus. *J. Biol. Chem.*, 265, 8650-8657.

-35-

- Gommel, D., Orci, L., Emig, E.M., Hannah, M.J., Ravazzola, M., Nickel, W., Helms, J.B., Wieland, F.T. and Sohn, K. (1999) p24 and p23, the major transmembrane proteins of COPI-coated transport vesicles, form hetero-oligomeric complexes and cycle between the organelles of the early secretory pathway. *FEBS Lett.*, 447, 179-185.
- 5 Hanada, K., Hara, T., Fukasawa, M., Yamaji, A., Umeda, M. and Nishijima, M. (1998) Mammalian cell mutants resistant to a sphingomyelin-directed cytolysin. *J. Biol. Chem.*, 273, 33787-33794.
- Heidler, S.A. and Radding, J.A. (2000) Inositol phosphoryl transferases from human pathogenic fungi. *Biochim. Biophys. Acta.*, 1500, 147-152.
- 10 Holthuis J.C., Nichols, B.J., Dhruvakumar, S. And Pelham, H.R. (1998) Two syntaxin homologues in the TGN/endosomal system of yeast. *EMBO J.*, 17, 113 - 126
- Holthuis, J.C., Pomorski, T., Raggars, R.J., Sprong, H. and Van Meer, G. (2001) The organizing potential of sphingolipids in intracellular membrane transport. *Physiol. Rev.*, 81, 1689-1723.
- 15 Jeckel, D., Karrenbauer, A., Birk, R., Schmidt, R.R. and Wieland, F. (1990) Sphingomyelin is synthesized in the cis Golgi. *FEBS Lett.*, 261, 155-157.
- Kallen, K.-J., Allan, D., Whatmore, J. and Quinn, P. (1994) Synthesis of surface sphingomyelin in the plasma membrane recycling pathway of BHK Cells. *Biochim. Biophys. Acta*, 1191, 52-58.
- 20 Kolesnick, R. and Hannun, Y.A. (1999) Ceramide and apoptosis. *Trends Biochem. Sci.*, 24, 224-225.
- Lauer, S.A., Ghorri, N. and Haldar, K. (1995) Sphingolipid synthesis as a target for chemotherapy against malaria parasites. *Proc. Natl. Acad. Sci. USA*, 92, 9181-9185.
- Levine, T.P., Wiggins, C.A. and Munro, S. (2000) Inositol phosphorylceramide synthase is located in the Golgi apparatus of *Saccharomyces cerevisiae*. *Mol. Biol. Cell*, 11, 2267-2281.
- 25 Lipsky, N.G. and Pagano, R.E. (1985) Intracellular translocation of fluorescent sphingolipids in cultured fibroblasts. *J. Cell Biol.*, 100, 27-34.
- Lochnit, G., Dennis, R. D., and Geyer, R. (2000) Phosphorylcholine substituents in nematodes: structures, occurrence and biological implications. *Biol Chem* 381, 839-847
- 30

-36-

- Luberto, C. and Hannun, Y.A. (1998) Sphingomyelin synthase, a potential regulator of intracellular levels of ceramide and diacylglycerol during SV40 transformation. *J. Biol. Chem.*, 273, 14550-14559.
- 5 Luberto, C., Stonehouse, M.J., Collins, E.A., Marchesini, N., El-Bawab, S., Vasil, A.I., Vasil, M.L. and Hannun, Y.A. (2003) Purification, characterization, and identification of a sphingomyelin synthase from *Pseudomonas aeruginosa*. *J. Biol. Chem.*, 278, 32733-32743.
- 10 Malgat, M., Maurice, A. and Baraud, J. (1986) Sphingomyelin and ceramide-phosphoethanolamine synthesis by microsomes and plasma membranes from rat liver and brain. *J. Lipid Res.*, 27, 251-260.
- Malgat, M., Maurice, A., and Baraud, J. (1987) *J. Lipid Res.* 28, 138-143
- Marggraf, W.-D. and Kanfer, J.N. (1984) The phosphorylcholine receptor in the phosphatidylcholine:ceramide cholinephosphotransferase reaction. *Biochim. Biophys. Acta*, 793, 346-353.
- 15 Nagiec, M.M., Nagiec, E.E., Baltisberger, J.A., Wells, G.B., Lester, R.L. and Dickson, R.C. (1997) Sphingolipid synthesis as a target for antifungal drugs. *J. Biol. Chem.*, 272, 9809-9817.
- Neuwald, A.F. (1997) An unexpected structural relationship between integral membrane phosphatases and soluble haloperoxidases. *Protein Sci.*, 6, 1764-1767.
- 20 Pettus, B.J., Chalfant, C.E. and Hannun, Y.A. (2002) Ceramide in apoptosis: an overview and current perspectives. *Biochim. Biophys. Acta*, 1585, 114-125.
- Riboni, L., Viani, P., Bassi, R., Giussani, P. and Tettamanti, G. (2001) Basic fibroblast growth factor-induced proliferation of primary astrocytes. *J. Biol. Chem.*, 276, 12797-12804.
- 25 Rietveld, A., Neutz, S., Simons, K. and Eaton, S. (1999) Association of sterol- and glycosylphosphatidylinositol-linked proteins with *Drosophila* raft lipid microdomains. *J. Biol. Chem.*, 274, 12049-12054.
- Satouchi, K., Hirano, K., Sakaguchi, M., Takehara, H. and Matsuura, F. (1993) Phospholipids from the free-living nematode *Caenorhabditis elegans*. *Lipids*, 28, 837-30 840.



-37-

- Schultz, J., Ponting, C.P., Hofmann, K. and Bork, P. (1997) SAM as a protein interaction domain involved in developmental regulation. *Protein Sci*, 6, 249-253.
- Simons, K. and Toomre, D. (2000) Lipid rafts and signal transduction. *Nat. Rev. Mol. Cell Biol.*, 1, 31-39.
- 5 Sprong H., Degroote, S., Claessens T., van Drunen, J., Oorschot, V., Westerink, B.H., Hirabayashi, Y., Klumperman, J., van der Shuijs, P. and van Meer, G. (2001) Glycosphingolipids are required for sorting melanosomal proteins in the Golgi complex. *J. Cell Biol.*, 155, 369 - 380.
- Trotter, P.J. (2000) A novel pathway for transport and metabolism of a fluorescent phosphatidic acid analog in yeast. *Traffic*, 1, 425-434.
- 10 Ullman, M.D. and Radin, N.S. (1974) The enzymatic formation of sphingomyelin from ceramide and lecithin in mouse liver. *J. Biol. Chem.*, 249, 1506-1512.
- van Helvoort, A., Stoorvogel, W., van Meer, G. and Burger, K.N.J. (1997) Sphingomyelin synthase is absent from endosomes. *J. Cell Sci.*, 110, 781-788.
- 15 van Helvoort, A., van 't Hof, W., Ritsema, T., Sandra, A. and van Meer, G. (1994) Conversion of diacylglycerol to phosphatidylcholine on the basolateral surface of epithelial MDCK cells. *J. Biol. Chem.*, 269, 1763-1769.
- Voelker, D.R. and Kennedy, E.P. (1982) Cellular and enzymic synthesis of sphingomyelin. *Biochem.*, 21, 2753-2759.
- 20 Waggoner, D.W., Xu, J., Singh, I., Jasinska, R., Zhang, Q.X. and Brindley, D.N. (1999) Structural organization of mammalian lipid phosphate phosphatases: implications for signal transduction. *Biochim. Biophys. Acta*, 1439, 299-316.

-38-

## Claims

1. An isolated polypeptide comprising one or more of the amino acid motifs selected from the group consisting of a sequence with at least 80% identity to any of
- 5
- (a) P-L-X-D-X(35,75)-R-R-X(8)-[YF]-X(2)-R-X(6)-T
- (b) C-X-D-X(3)-S-G-H-T
- 10
- (c) H-Y-[TS]-X-D-[VI]-X(3)-[FYI]-X(6)-F-X(2)-Y-H.
2. A polypeptide according to claim 1 that is derived from the group consisting of *Animalia*, *Alveolata* and *Kinetoplastida*.
- 15
3. A polypeptide according to claim 1 or 2 selected from the group comprising any of the SEQ ID No. 1 - 11 or at least 70% similarity thereto.
4. A polypeptide according to claim 1 or 2 comprising an amino acid sequence with at least 70 % similarity to any of the SEQ ID No. 12 - 22.
- 20
5. A polypeptide according to any one of the previous claims comprising an amino acid sequence with at least 20 % identity to any of the SEQ ID No. 12 - 22.
6. A polypeptide according to claim 5 comprising an amino acid sequence
- 25
- with at least 30 % identity to SEQ ID No. 12.
7. A polypeptide according to claim 5 comprising an amino acid sequence with at least 40 % identity to any of the SEQ ID No. 19 - 21.
- 30
8. A polypeptide according to any one of the claims 1 - 3 comprising an amino acid sequence with at least 22 % identity to SEQ ID No. 22.

-39-

9. A polypeptide according to any one of the claims 1 - 6 with sphingomyelin synthase activity.
10. A polypeptide according to any one of the claims 1 - 5 and 7 with  
5 ethanolamine phosphorylceramide synthase activity.
11. A polypeptide according to any one of the claims 1 - 5 and 8 with one or more of the activities selected from the group consisting of phosphatidylcholine:glycoprotein cholinephosphotransferase and phosphatidylcholine:glycolipid  
10 cholinephosphotransferase.
12. A nucleotide sequence selected from the group consisting of a nucleotide sequence coding for any of the amino acid sequences as described in claim 9 and an anti sense nucleotide sequence that is complementary thereto.  
15
13. A nucleotide sequence selected from the group consisting of a nucleotide sequence coding for any of the amino acid sequences as described in claim 10 and an anti sense nucleotide sequence that is complementary thereto.
- 20 14. A nucleotide sequence selected from the group consisting of a nucleotide sequence coding for any of the amino acid sequences as described in claim 11 and an anti sense nucleotide sequence that is complementary thereto.
- 25 15. A plasmid comprising any of the nucleotide sequences described in any of the claims 12, 13 or 14.
16. A vector comprising any of the nucleotide sequences described in any of the claims 12, 13 or 14.
- 30 17. A (micro)organism or cell line in which any of the nucleotide sequences described in claim 12 was introduced.

-40-


18. A (micro)organism or cell line in which any of the nucleotide sequences described in claim 13 was introduced.

5 19. A (micro)organism or cell line in which any of the nucleotide sequences described in claim 14 was introduced.

10 20. A process for producing sphingomyelin synthase comprising the expression of any one of the nucleotide sequences described in claim 12 in a (micro)organism or cell line of claim 17 and the isolation of sphingomyelin synthase.

21. A process for producing sphingomyelin comprising the expression of the nucleotide sequences described in claim 12 in a (micro)organism or cell of claim 17 and the isolation of sphingomyelin.

15 22. Use of one of more of the nucleotide sequences of claim 12 to influence the reaction



20 *in vivo* or *in vitro*.

23. Use of one of more of the nucleotide sequences of claim 12 to identify or develop compounds influencing the reaction



*in vivo* or *in vitro*.

24. A process for producing ethanolamine phosphorylceramide synthase comprising

-41-

the expression of any one of the nucleotide sequences described in claim 13 in a (micro)organism or cell line of claim 18 and the isolation of ethanolamine phosphorylceramide synthase.


5 25. A process for producing ethanolamine phosphorylceramide comprising the expression of the nucleotide sequences described in claim 13 in a (micro)organism or cell line of claim 18 and the isolation of ethanolamine phosphorylceramide.

10 26. Use of any one of the nucleotide sequences of claim 13 to influence the reaction



15 *in vivo* or *in vitro*.

27. Use of any one of the nucleotide sequences of claim 13 to identify or develop compounds influencing the reaction



20

*in vivo* or *in vitro*.

28. The application of the compounds of claim 23 or 27 in medical use.

25 29. The application of the compounds of claim 28 for the manufacture of medicaments treating a disease selected from the group consisting of cancer, metabolic diseases and diseases caused by parasites.

30 30. A process for producing phosphatidyl:glycoprotein cholinephosphotransferase or phosphatidyl:glycolipid cholinephosphotransferase comprising the expression of any one of the corresponding nucleotide sequences

-42-

described in claim 14 in a (micro)organism or a cell line of claim 19 and the isolation of phosphatidyl:glycoprotein cholinephosphotransferase or phosphatidyl:glycolipid cholinephosphotransferase.

- 5 31. A process for producing phosphorylcholine-substituted glycoprotein or phosphorylcholine-substituted glycolipid comprising the expression of the corresponding nucleotide sequences described in claim 14 in a (micro)organism or cell of claim 19 and the isolation of phosphorylcholine-substituted glycoprotein or phosphorylcholine-substituted glycolipid .

10

32. Use of one of more of the nucleotide sequences of claim 14 to influence the reaction



15

*in vivo* or *in vitro*.

33. Use of one of more of the nucleotide sequences of claim 14 to identify or develop compounds influencing the reaction

20



*in vivo* or *in vitro*.

- 25 34. The application of the compounds of claim 33 in medical use.

35. The application of the compounds of claim 34 for the manufacture of a medicament treating a disease caused by parasitic nematodes.

- 30 36. A process to isolate candidates for functional genes of a previously unidentified

-43-

enzyme with known activity from a huge database by combining at least four characteristics based on data from bio-informatics and from biochemistry, viz.

– presence of a sequence motif shared with previously identified enzymes having a related function

5      – biochemical function of the gene should be unknown until now

– no structural homologues in an organism that does not contain the enzyme

– ability to mediate a reaction catalysed by the unidentified enzyme upon its heterologous expression in an organism or cell lacking said enzyme activity.

10      37.      A process to isolate candidates for functional genes according to claim 36 characterized by also considering the presence or non-presence of transmembrane domains depending on the working mechanism of the enzyme in relation to the membrane.

15

20

25

-44-

## Abstract

## Newly identified cholinephosphotransferases and ethanolaminephosphotransferases

5 The present invention relates to polypeptides comprising one or more of the amino acid motifs selected from the group consisting of a sequence with at least 80% identity to any of

(a) P-L-X-D-X(35,75)-R-R-X(8)-[YF]-X(2)-R-X(6)-T

(b) C-X-D-X(3)-S-G-H-T

(c) H-Y-[TS]-X-D-[VI]-X(3)-[FYI]-X(6)-F-X(2)-Y-H,

10 which transfer phosphocholine and phosphoethanolamine, nucleotide sequences coding for any of these polypeptides and nucleotide sequences complementary thereto, plasmids, vectors and a (micro)organism or cell comprising said nucleotide sequences. Furthermore, the present invention relates to processes to produce cholinephosphotransferases and ethanolaminephosphotransferases like sphingomyelin  
15 synthase, ethanolamine phosphorylceramide synthase, phosphatidylcholine:glycoprotein cholinephosphotransferase and phosphatidylcholine:glycolipid cholinephosphotransferase. The present invention also provides the application of said nucleotide sequences to influence the equilibrium reactions or to develop compounds influencing the equilibrium reactions wherein said transferases are involved and the  
20 application of said compounds in medical use. Finally, a process has been provided to isolate candidates for functional genes of a previously unidentified enzyme from a large database by isolating candidates for functional genes of a previously unidentified enzyme with known activity from a huge database by combining at least four characteristics based on data from bio-informatics and from biochemistry, viz.  
25 – presence of a sequence motif shared with previously identified enzymes having a related function  
– biochemical function of the gene should be unknown until now  
– no structural homologues in an organism that does not contain the enzyme  
– ability to mediate a reaction catalysed by the unidentified enzyme upon its  
30 heterologous expression in an organism or cell lacking said enzyme activity.






FIG. 1





FIG. 2

**FIG. 3**





FIG. 4

**FIG. 5**






FIG. 7

A

Hs SMS1 1 MKEVYVKKKVDWL...MPV...E...HFTGQD...L...E...F...K...P...I...CRYSSD...G  
Hs SMS2 1 MAGPNQLC...RR...KHVAVWL...F...F...V...I...CNKHRLOG...T...L...T...V...L...E...P...I...K...Y...L...G...I  
Hs SMSr 1 MAGPNQLC...RR...KHVAVWL...F...F...V...I...CNKHRLOG...T...L...T...V...L...E...P...I...K...Y...L...G...I

Hs SMS1 58 DRLED...PTLK...EHH...LEAH...K...H...LN...I...V...I...TP...G...F...S...K...I...K...G...G...Y...K...  
Hs SMS2 66 ND...ETAK...EEN...LE...Q...G...D...N...Y...R...P...A...E...V...E...K...G...N...G...K...P...H...S...L...S...G...I...R...K...G...T...K...Y...  
Hs SMSr 66 KRL...GL...RK...L...K...I...I...D...V...L...M...G...Y...N...G...D...M...P...F...I...S...G...S...G...I...R...K...G...T...K...Y...  
Hs SMS1 114 ...M...K...I...M...P...E...L...R...B...C...P...E...W...K...T...F...L...A...F...Y...A...B...C...F...U...L...T...T...V...M...V...H...E...R...V...P...P...K...E...C...P...P...L...P...D...T...F...D...H...F...  
Hs SMS2 131 ...M...K...I...M...P...E...L...R...B...C...P...E...W...K...T...F...L...A...F...Y...A...B...C...F...U...L...T...T...V...M...V...H...E...R...V...P...P...K...E...C...P...P...L...P...D...T...F...D...H...F...  
Hs SMSr 131 ...M...K...I...M...P...E...L...R...B...C...P...E...W...K...T...F...L...A...F...Y...A...B...C...F...U...L...T...T...V...M...V...H...E...R...V...P...P...K...E...C...P...P...L...P...D...T...F...D...H...F...

Hs SMS1 178 ...R...V...W...A...F...S...C...E...I...N...O...H...I...L...V...G...L...W...L...Q...W...L...L...K...Y...K...S...I...R...R...E...F...C...I...G...T...Y...L...Y...R...O...I...T...M...Y...V...T...T...L...P...V...G...M...H...F...  
Hs SMS2 122 ...R...V...W...A...F...S...C...E...I...N...O...H...I...L...V...G...L...W...L...Q...W...L...L...K...Y...K...S...I...R...R...E...F...C...I...G...T...Y...L...Y...R...O...I...T...M...Y...V...T...T...L...P...V...G...M...H...F...  
Hs SMSr 165 ...R...V...W...A...F...S...C...E...I...N...O...H...I...L...V...G...L...W...L...Q...W...L...L...K...Y...K...S...I...R...R...E...F...C...I...G...T...Y...L...Y...R...O...I...T...M...Y...V...T...T...L...P...V...G...M...H...F...

Hs SMS1 243 ...C...C...P...K...I...G...D...W...A...C...L...R...I...L...I...G...G...G...L...S...I...G...S...H...I...C...G...D...Y...L...S...G...H...T...V...L...T...L...Y...L...F...I...K...E...Y...S...R...R...L...W...Y...  
Hs SMS2 187 ...C...C...P...K...I...G...D...W...A...C...L...R...I...L...I...G...G...G...L...S...I...G...S...H...I...C...G...D...Y...L...S...G...H...T...V...L...T...L...Y...L...F...I...K...E...Y...S...R...R...L...W...Y...  
Hs SMSr 260 ...C...C...P...K...I...G...D...W...A...C...L...R...I...L...I...G...G...G...L...S...I...G...S...H...I...C...G...D...Y...L...S...G...H...T...V...L...T...L...Y...L...F...I...K...E...Y...S...R...R...L...W...Y...

Hs SMS1 309 ...I...M...I...C...W...L...L...S...A...A...G...I...C...I...L...A...H...E...H...Y...T...I...D...V...I...A...Y...I...T...R...L...F...W...Y...H...T...M...A...N...Q...V...L...K...E...C...S...O...M...N...L...A...R...W...W...R...  
Hs SMS2 252 ...I...M...I...C...W...L...L...S...A...A...G...I...C...I...L...A...H...E...H...Y...T...I...D...V...I...A...Y...I...T...R...L...F...W...Y...H...T...M...A...N...Q...V...L...K...E...C...S...O...M...N...L...A...R...W...W...R...  
Hs SMSr 324 ...I...M...I...C...W...L...L...S...A...A...G...I...C...I...L...A...H...E...H...Y...T...I...D...V...I...A...Y...I...T...R...L...F...W...Y...H...T...M...A...N...Q...V...L...K...E...C...S...O...M...N...L...A...R...W...W...R...

Hs SMS1 373 ...P...Q...F...E...K...H...V...Q...G...I...V...R...S...Y...H...N...P...T...W...P...V...H...L...G...R...Q...V...A...Y...R...V...N...D...T...  
Hs SMS2 317 ...I...F...Y...F...E...K...H...V...Q...G...I...V...R...S...Y...H...N...P...T...W...P...V...H...L...G...R...Q...V...A...Y...R...V...N...D...T...  
Hs SMSr 384 ...M...P...S...F...F...E...C...H...V...Q...G...I...V...R...S...Y...H...N...P...T...W...P...V...H...L...G...R...Q...V...A...Y...R...V...N...D...T...

B

Hs SMS1 109 PLPD 213 RREFC...I...G...T...Y...L...Y...R...C...I...T...M...Y...V...T...  
Hs SMS2 112 PLPD 167 RREFC...I...G...T...Y...L...Y...R...C...I...T...M...Y...V...T...  
Ce SMS1 175 PLPD 220 RREFC...I...G...T...Y...L...Y...R...C...I...T...M...Y...V...T...  
Ce SMS2 89 PLPD 133 RREFC...I...G...T...Y...L...Y...R...C...I...T...M...Y...V...T...  
Ce SMS3 65 PLPD 110 RREFC...I...G...T...Y...L...Y...R...C...I...T...M...Y...V...T...  
Pt SMS1 181 PLPD 211 RREFC...I...G...T...Y...L...Y...R...C...I...T...M...Y...V...T...  
Pt SMS2 112 PLPD 161 RREFC...I...G...T...Y...L...Y...R...C...I...T...M...Y...V...T...  
Hs SMSr 185 PLPD 230 RREFC...I...G...T...Y...L...Y...R...C...I...T...M...Y...V...T...  
Dm SMSr 232 PLPD 277 RREFC...I...G...T...Y...L...Y...R...C...I...T...M...Y...V...T...  
Ce SMSr 214 PLPD 259 RREFC...I...G...T...Y...L...Y...R...C...I...T...M...Y...V...T...  
Ce SMSd 111 PLPD 163 RREFC...I...G...T...Y...L...Y...R...C...I...T...M...Y...V...T...  
consensus PLPD RxxxxbxxxxbxxxxRxxxxbT

Hs SMS1 277 CGDY...L...S...G...H...T...  
Hs SMS2 221 CGDY...L...S...G...H...T...  
Ce SMS1 288 CGDY...L...S...G...H...T...  
Ce SMS2 202 CGDY...L...S...G...H...T...  
Ce SMS3 175 CGDY...L...S...G...H...T...  
Pt SMS1 268 CGDY...L...S...G...H...T...  
Pt SMS2 216 CGDY...L...S...G...H...T...  
Hs SMSr 350 CGDY...L...S...G...H...T...  
Dm SMSr 322 CGDY...L...S...G...H...T...  
Ce SMSr 267 CGDY...L...S...G...H...T...  
consensus CGDxbxSGHT

Hs SMS1 328 HYTD...V...V...A...Y...V...I...T...A...L...F...W...Y...H...  
Hs SMS2 272 HYTD...V...V...A...Y...V...I...T...A...L...F...W...Y...H...  
Ce SMS1 339 HYTD...V...V...A...Y...V...I...T...A...L...F...W...Y...H...  
Ce SMS2 253 HYTD...V...V...A...Y...V...I...T...A...L...F...W...Y...H...  
Ce SMS3 220 HYTD...V...V...A...Y...V...I...T...A...L...F...W...Y...H...  
Pt SMS1 316 HYTD...V...V...A...Y...V...I...T...A...L...F...W...Y...H...  
Pt SMS2 265 HYTD...V...V...A...Y...V...I...T...A...L...F...W...Y...H...  
Hs SMSr 344 HYTD...V...V...A...Y...V...I...T...A...L...F...W...Y...H...  
Dm SMSr 401 HYTD...V...V...A...Y...V...I...T...A...L...F...W...Y...H...  
Ce SMSr 373 HYTD...V...V...A...Y...V...I...T...A...L...F...W...Y...H...  
Ce SMSd 288 HYTD...V...V...A...Y...V...I...T...A...L...F...W...Y...H...  
consensus HYTDVxbnQxxxxnnxbFxyH

FIG. 8



**FIG. 9****Sequence listings**

Sequence listings 1 - 11: conserved sequence motifs of phosphotransferases as indicated in figure 8 B;

sequence listing 1: partial polypeptide sequences of *hu* SMS1  
sequence listing 2: partial polypeptide sequences of *hu* SMS2  
sequence listing 3: partial polypeptide sequences of *ce* SMS1  
sequence listing 4: partial polypeptide sequences of *ce* SMS2  
sequence listing 5: partial polypeptide sequences of *ce* SMS3  
sequence listing 6: partial polypeptide sequences of *pf* SMS1  
sequence listing 7: partial polypeptide sequences of *pf* SMS2  
sequence listing 8: partial polypeptide sequences of *hu* SMSr  
sequence listing 9: partial polypeptide sequences of *dm* SMSr  
sequence listing 10: partial polypeptide sequences of *ce* SMSr  
sequence listing 11: partial polypeptide sequences of *ce* SMSdr

**Sequence listing 12: *hu*SMS1**

MKEVVYWSPKKVADWLENAMPEYCEPLEHFTGQDLNLTQEDFKKPPLCRVSSDN  
GQRLDMIETLKMEHHLEAHKNGHANGHLNIGVDIPTPDGSFSIKIKPNGMPNGYRK  
EMIKIPPELERSQYPMEWGKTFLAFLYALSCFVLTTVMISVVHERVPPKEVQPPLPD  
TFFDHFNRVQWAFSICEINGMILVGLWLIQWLLLKYKSISRRFFCIVGTLYLRCITM  
YVTTLVPVPGMHFNCSPKLFGDWEAQLRRIMKLIAGGGLSITGSHNMCGDYLYSGHTV  
MLTLTYLFIKEYSPRRLWWYHWICWLLSVVGIFCILLAHDHYTVDVVVAYYITTRLF  
WWYHTMANQQVLKEASQMNLLARVWWYRPFQYFEKNVQGIVPRSYHWPFPWPV  
VHLSRQVKYSRLVNDT

Sequence listing 13: *huSMS2*

MDIETAKLEEHLNQPSDPTNTYARPAEPVEEENKNGNGKPKSLSSGLRKGTKKYPD  
YIQIAMPTESRNKFPLEWWKTGIAFIYAVFNLVLTTVMITVVHERVPPKELSPPLPDKF  
FDYIDRVKWAFSVSEINGILVGLWITQWLFLRYKSIVGRRFCFIIGTLYLYRCITMYVT  
TLPVPGMHFQCAPKLNGDSQAKVQRILRLISGGGLSITGSHILCGDFLFSGHTVTLTLT  
YLFKEYSPRHFWWYHLICWLLSAAGIICILVAHEHYTIDVIAYYITTRLFWWYHSMA  
NEKNLKVSSQTNFLSRAWWFPIFYFFEKNVQGSIPCCFSWPLSWPPGCFKSSCKKYSR  
VQKIGEDNEKST

Sequence listing 14: *ceSMS1*

MKMSWNHQYTNYGSIADDNGDEEKAENSEGAAAEKVEKQHDDDGVVVHEETDGV  
ASSRSSHHDKQKPGETKKSGDGKMDDDDIITTARSSSRICGSAASSSDSETADDAPL  
LPDEGPSHAVRLEMPGDKPASPHDRFPKTPKTLVAFMLLVAAAGNTITLSWIHER  
YPLTPPLPDIVFELPKIPWGLRLCENLMIGSFVSLVLILFHRHRWIVLRRLCFIGSILYG  
MRCITMMVTPVPKADEDFECSPRFGENATFSLIVMRGVWSMFGLGLNLFDNQKVVL  
CGDYIYSGHTLVLVVSALFIGEYSPRRFYILHWLSWLVCSVGVIPLVLSHGHTIDVIL  
SYFACTRVFWAYHTQAAHPSIRLSVQNHQAKEFWFLLRWFEGBIRRPVPRRFDCPIS  
YSQTPVDYSFLPWFSFFFQSNPMMFPGAFTFYHTQNHKSTMSLPK

Sequence listing 15: *ceSMS2*

MTNSSEFTDVLQSRDPCVSNQIVINIDPIDPEPTPIRKEFTCEDTFHHEHHGNSEGFKTL  
TAFCLCLMSAFLNFFLLTVIHDVVPQPLPDLTFMIPQQRWAWSVGDLSTVSSVVA  
FTIIFLHHQRWIVLRRTFLLGAMYGLRAVILGVTFLPPSFHNRDEICQPQVNRTAMYG  
MEIATRFLTIVITLGLTSGQDKILCGDLMFSGHTVVLTIMYFVQLQYTPRGLVILRYIA  
APITFLGIAALVVSOGHYTMDVLIAYWLTSHVFWSYHQIFEMRKDDRPQAPLSRLW  
WFWLCYWFESDVADGKLVNKWNWPLEGPQRMHTIMNRINYKLQ

Sequence listing 16: *ceSMS3*

MGSVSKTVISARGASPDDEQNGTKNGISNGSEWAKCIFLFFFLFIAGMSNWAVLAYT  
HDYVPRESLPDIVFSLVSEQRWASSLGDFCVAlCIVMLGALLVIHQHRGTILKRVVFC  
AGTLYAMRSVTLAATQLPSGYTDNQGRCDQVESEAGVFFGRLFEQTIRIGFQSKDQ  
MLCGDLLFSGHTLVMVTCSLAVAYYLPKSIKPLQWVSHVACLIGMICMTISRTHYTID  
VVIAYWLSNMVFRMYHAYCEVDMCMERRKSILYSWWPCRIVDWLEQDIVPGRLEN  
RCQLPWRRSTPRGQERGGASAESSDSSVTMCDNITTSHHQKHVSISSSSTYPLPC

Sequence listing 17: *pfSMS1*

MIEGNINANTTHQNTTNKIEKNFIKEKDIINNDTIKILIEHNNSFNDESTNYITTFNDIK  
DKHYNHKDSYSDNKGKIKTLRSNFSDIQDEVIITNIGHYFEGQENIKKSVEIKNCOPYKK  
KMLKIFLRRLLVCATIIGIGICIQCIFYILSDTYKYTGDEPLKDRLEHIFKEIPAFMNTPFV  
NGSIMFFLAITLLRFGLFCPLLLSITILIRIILMLSFIYCIRSFFTYVTTLPCPIPTCQPLKHK  
LVENLYTFYLIITAQVYECTDLVISGHTAFTTLLTFFWFFYERNIYVKTITFLYSIYTYIII  
SRFHYTVDVLMGYVFGGSVFLFYHYLVDVAARRYALNTSVFPQTYGFSGSFTDRFQ  
VFQYFIRAITYLEALDHRMNFALSVDKEWNCFCSCVPVNKNSLLIKKKNVRNEEYYD  
FSDHFYHSYAGNGTYNLSTIRNIIKEFKRFFGMNKK

Sequence listing 18: *pfSMS2*

MNKYEYFYSPIQLLHLILLRPILYENYTYDENDKSSIGTDMYEINMNRKMSNISISR  
STINEEEILSEYRLCKILLIKLMFALLFLIALIQGFFMYSDSYKSNTQPLSDRIHDLF  
GNPPKWISYKLSNTLIAILTSFLKILFNISYLSIAIICRFLYTVGSFYIRGLLIYVTS  
LPATLETCLPLESGNFLFNLLQIKINTNLVYVCADLIVSGHSFSTTIFLMFSFYIINNVIKFI  
TFSCFIYAMIGFIHYTSDVLLGIIFGVFMFSFYHIMLDISSQYYIFNKLFEIKIISNNKNI  
HAKPFFLRFFVARIFFKIIPYLEGLNYTLDYAINKNNDLSTFCNCDHDNNKIPLFSFYK  
PITEDKIINYSDHLYHSYAGDGTINFLFWKFLKTIKKGLHK

Sequence listing 19: *huSMSr*

MAGPNQLCIRRWTTKHVAVWLKDEGFFEYVDILCNKHRLDGITLLTLTEYDLRSPPL  
EIKVLGDIKRLMLSVRKLQKIHIDVLEEMGYNSDSPMGSMTPFISALQSTDWLCNGEL  
SHDCDGPITDLNSDQYQYMNGKNKHSVRRLDPEYWKTILSCIYVFIVFGFTSFIMVIV  
HERVPDMQTYPPPLPDIFLDSVPRIPWAFAMTEVCGMILCYTWLLVLLLHKHRSILLRRL  
CSLMGTVFLLRCFTMFVTSLSVPGQHLQCTGKIYGSVWEKLHRAFAIWSGFGMTLTG  
VHTCGDYMFSGHTVVLTMLNFFVTEYTPRSWNFLHTLSWVLNLFGIFFILAAHEHYSI  
DVFIAFYITTRLFLYYHTLANTRAYQQSRRARIWFPMFSECNVNGTVPNEYCWPFS  
KPAIMKRLIG

Sequence listing 20: *dmSMSr*

MCDGEIGDPVTQPRSEGGGLVTMDQETRTHYLDAATDKHLTNGSPDPEPVDPLLVA  
QWSIENVTSWATCMEHFSRTLDCLRQEADGEVLLSLTEEDVRDMRYKLGKLTFG  
ELKKFWIAVLKLQLLVKNSSAESVILGIECHGNGNSVYMPLASTGCGPPSSSTCPCPQ  
AECPSYVSDCDTYLRMGGRYPPEYFKTAMSLGYSFVVTWITSLTMVIVHERVPDM  
KRYPPPLPDIFLDNVPHIPWAFNMCEITGSLLFTTWVVVLTFHKYRLVLLRRFFALAGTV  
FLLRCVTMLITSLSVPGTHLQCSQKDAIDDPNVDMVGALIIRMSRAYRIWSGLGMSI  
QGVRTCGDYMFSGHTVALTLLNFFITEYTPRNLYFLHTLTWLLNMFGIFFILAAHEHY  
SIDVFVAFYITSRFLYYHTLANNRALMQSDSKRTRVWFPMFSYFESSVDGMVPNEY  
DTLGSLIDGIEQIFKAKDQLAISVKRCWLDAPLSGNSSAHMFGGESEQCLRNGTASA  
AFFSPHQSLIGGLGGQRSQTHLNSAQSGSSTPTPATSAPTKSLPTQKKTFRDASVDPFS  
RTTFAAVQQAENVKDSPMKEKKHL

Sequence listing 21: *ceSMSr*

MLDNRPIPADPNEWRCEDVGNWLKKIGMAKYADLIAMKHKVDGKCLLALTDTDLK  
DPPVSINCLGDIKKILFAIEFLSQKVVEIGNSGVHHRSTPNGNGPSLKNSKDGLLVEYN  
EQNHLSISGEDVYTTTTRRAEIVEDEETLLDTLAKSSDGTSTVQLISREEIRQVERPDY  
FKSVAKLLIAFAYSSLSFLMTSFVMVLVHDRVPDTKTYPPPLPDIVLDNVPHIPWAFDM

CETIGLVLA VVWFTV LFFHNQ RVIVARRMF SLLGTV FLLRCFTML ITSLSVPGIHLQCE  
ARPNTTMQEKLHKA FHIWSNLGMSLHGVRSCGDYMFSGHTTVITMISHFITEYTPAD  
WTGLHTFTWVLNCF AIFLILAAHEHYSIDVFIAFYISSRMFLYYHAYAYNHAGITATD  
YRMRTWFPLGWFFEYGSQGKVENEFSLPINIRIPRRVFFAKSEEPKITPKSDSSRKRSS  
VVAAKQNGNSKNHTKKHN

Sequence listing 22: *ceSMSdr*

MCKSCENYGKFFFAM LKICIDNSSNFAMKKDAENENLLHAYEHDEQSSKYFIKPDSR  
YSIDDDISVKIDGKQLEVRKWPTLLATAMVGVGWLSNEVALAWVHERVPDDYHPLP  
DLFFSHFPEVKERLKIFGILGKFEKSEKKTSEFSSPIRGAIRIAEYIMMILLISALLVMFTH  
QHRWIVIRRVFFCIAMAYSFRALCVTIFQVPVPSINTYCAPKSNSSLELVAGR VVKMF  
WSAGIEQLRPRELCGDLIVSGHTLTIFTAFLVKTYAPQRLQPLSHIYHVLAFTALFSIL  
LARKHYMIDIVLGYTVSTRIFMEYHALAASYHNRTFETNPLAWSFWSFFPIFECDAPA  
NMHNHLLLYNRSTSSKNVSTLKKSRRSFE




FIG. 10




FIG. 11




FIG. 12






FIG. 13



# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/NL04/000488

International filing date: 07 July 2004 (07.07.2004)

Document type: Certified copy of priority document

Document details: Country/Office: EP  
Number: 03078932.5  
Filing date: 18 December 2003 (18.12.2003)

Date of receipt at the International Bureau: 11 March 2005 (11.03.2005)

Remark: Priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse